

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Comparative Efficacy and Acceptability of Psychotherapies for Post-traumatic Stress Disorder in Children and Adolescents: Study Protocol for a Systematic Review and Network Meta-Analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020198
Article Type:	Protocol
Date Submitted by the Author:	20-Oct-2017
Complete List of Authors:	Zhang, Yuqing; The First Affiliated Hospital of Chongqing Medical University, Department of Neurology Zhou, Xinyu; The First Affiliated Hospital of Chongqing Medical University, Department of Psychiatry Yang, Lining; The First Affiliated Hospital of Chongqing Medical University, Department of Neurology Hetrick, Sarah; University of Melbourne, Centre for Youth Mental Health Weisz, John; Harvard University, Department of Psychology Cuijpers, Pim; VU University Amsterdam, Department of Clinical Psychology Barth, Juergen; University Hospital and University of Zurich, Institute for Complementary and Integrative Medicine Del Giovane, Cinzia; University of Modena and Reggio Emilia, Clinical and Diagnostic Medicine and Public Health Yuan, Shuai; The First Affiliated Hospital of Chongqing Medical University, Department of Neurology Cohen, David; Institut des Systèmes Intelligents et de Robotiques, UPMC Univ Paris 06, Department of Child and Adolescent Psychiatry Gillies, Donna; Western Sydney Local Health District, Mental Health Jiang, Xiaofeng; The First Affiliated Hospital of Chongqing Medical University, Department of Neurology Teng, Teng; The First Affiliated Hospital of Chongqing Medical University, Department of Neurology Xie, Peng; The First Affiliated Hospital of Chongqing Medical University, Department of Neurology; Chongqing Medical University, Institute of Neuroscience and the Collaborative Innovation Center for Brain Science
Keywords:	post-traumatic stress disorder, Child & adolescent psychiatry < PSYCHIATRY, psychotherapy, network meta-analysis, systematic review

SCHOLARONE™
Manuscripts

1
2
3 **Comparative Efficacy and Acceptability of Psychotherapies for Post-traumatic Stress Disorder**
4 **in Children and Adolescents: Study Protocol for a Systematic Review and Network**
5 **Meta-Analysis**
6
7
8
9

10 Yuqing Zhang,¹ Xinyu Zhou,² Lining Yang,¹ Sarah E. Hetrick,³ John R. Weisz,⁴ Pim Cuijpers,⁵ Jürgen Barth,⁶ Cinzia Del
11 Giovane,⁷ Shuai Yuan,¹ David Cohen,⁸ Donna Gillies,⁹ Xiaofeng Jiang,¹ Teng Teng,¹ Peng Xie¹
12
13
14
15

16 ¹ Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute
17 of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing,
18 China
19
20

21 ² Department of Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
22

23 ³ Orygen, The National Centre of Excellence in Youth Mental Health, and the Centre of Youth Mental Health, University
24 of Melbourne, Melbourne, Australia
25
26

27 ⁴ Department of Psychology, Harvard University, Cambridge, MA, USA
28

29 ⁵ Department of Clinical, Neuro and Developmental Psychology, Amsterdam Public Health research institute, Vrije
30 Universiteit Amsterdam, The Netherlands
31

32 ⁶ Institute for Complementary and Integrative Medicine, University Hospital and University of Zurich, Zurich,
33 Switzerland
34
35

36 ⁷ Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena,
37 Italy
38
39

40 ⁸ Department of Child and Adolescent Psychiatry, Hôpital Pitié-Salpêtrière, Institut des Systèmes Intelligents et
41 Robotiques, Université Pierre et Marie Curie, Paris, France
42

43 ⁹ Western Sydney Local Health District - Mental Health, Westmead, Australia
44
45
46

47 YZ, XZ and LY contributed equally to this work.
48
49
50

51 **Direct correspondence to:**

52 Prof Peng Xie, Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong
53 District, Chongqing, China; E-mail: xiepeng973@126.com.
54
55
56

1
2
3 Keywords: post-traumatic stress disorder, child, adolescent, psychotherapy, network meta-analysis, systematic review
4

5 Word count: 3143.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ABSTRACT

Introduction: Post-traumatic stress disorder (PTSD) is common among children and adolescents who are exposed to trauma, and it is often associated with significant negative impacts on their psychosocial functioning and quality of life. Many types of psychotherapies have been found to be effective for PTSD in children and adolescents. However, due to the lack of direct comparisons between different psychotherapies, the hierarchy of treatment efficacy is still unclear. Therefore, we plan to conduct a systematic review and network meta-analysis to evaluate the efficacy and acceptability of various types of psychotherapies for PTSD in children and adolescents.

Methods and analysis: A systematic search will be conducted among eight electronic databases, including PubMed, Cochrane, EMBASE, Web of Science, PsycINFO, CINAHL, PILOTS and ProQuest Dissertations, from inception to October 2017. Randomised controlled trials (RCTs), regardless of language, publication year, and publication type, comparing any structured psychotherapies for PTSD to any control condition or alternative treatment in children and adolescents (18 years old or less) will be included. The primary outcome will be efficacy at post-treatment, which is PTSD symptom severity measured by a rating scale reported by the child, parent, or a clinician. The secondary outcomes will include (1) efficacy at follow-up; (2) acceptability (all-cause discontinuation); (3) improvement of anxiety symptoms; (4) improvement of depressive symptoms, and (5) quality of life and functional improvement. Bayesian network meta-analyses for all relative outcome measures will be performed. We will conduct subgroup and sensitivity network meta-analyses to determine whether the findings are affected by study characteristics. The quality of the evidence contributing to network estimates of the primary outcome will be evaluated by the GRADE framework.

Ethics and dissemination: No ethical issues are foreseen. The results will be published in a peer-reviewed journal, which will be disseminated electronically and in print. This network meta-analysis may be updated to inform and guide the clinical management of PTSD in children and adolescents.

Trial registration number: PROSPERO CRD42016051786.

Strengths and limitations of this study

1. Bayesian network meta-analysis can simultaneously compare various types of treatments by integrating all the best evidence (direct and indirect evidence) to estimate the interrelations across all treatments and establish a treatment hierarchy for psychotherapies for post-traumatic stress disorder in children and adolescents.
2. A number of outcomes will be used to comprehensively assess efficacy at post-treatment and follow-up, acceptability, improvement of anxiety and depressive symptoms, and quality of life and functional improvement.
3. This study will help to guide clinical decision-making regarding the relative efficacy of various types of psychotherapy, and various delivery modalities, in the treatment of post-traumatic stress disorder in children and adolescents.
4. Subgroup and sensitivity network meta-analyses will help to find potential moderators that affect the efficacy of all included psychotherapies.
5. The limitations of included studies will be assessed using the Cochrane Collaboration's Risk of bias' 2.0 tool and the quality of evidence for network estimates of the primary outcome will be evaluated by the GRADE framework.

BACKGROUND

Trauma is common in children and adolescents. More than two thirds of young people have suffered at least one traumatic event,¹ with approximately 15.9% of whom go on to develop post-traumatic stress disorder (PTSD).² As described in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), PTSD diagnostic criteria includes four symptom clusters: (1) re-experiencing of the traumatic event, (2) avoidance of stimuli associated with the traumatic event, (3) negative alterations in cognition and mood, (4) hyperarousal.³ Trauma exposure is an essential factor in order to be able to diagnose PTSD, which include physical or sexual abuse, war or terrorism, natural or man-made disasters, witnessing domestic violence, catastrophic illnesses, vehicle or other accidents.^{4,5} PTSD is correlated with various adverse consequences for children and adolescents in cognitive, emotional, social, academic, and other functional domains.^{6,7} In addition, PTSD commonly co-occurs with other psychiatric comorbidities, such as depressive disorder,⁸ anxiety disorder,⁸ substance abuse,⁹ and ADHD.¹⁰ If children and adolescents do not receive adequate intervention, the symptoms of PTSD may be long-lasting, and have deleterious effects on well-being later in life.^{5,11}

Several forms of interventions have been applied to address PTSD symptoms in children and adolescents, from which psychotherapy is the mainstay of treatment.¹² Compared with psychotherapy, medication used in the treatment of PTSD in children and adolescents is limited because (1) the evidence of pharmacological treatments for children and adolescents with PTSD is scant, so that the benefit of medication is not clear,¹³ and, (2) medication usage has been associated with a series of safety concerns in children and adolescents, including evidence of a significant increase in the risk of suicidality in children and adolescents being treated with antidepressants.^{14,15} Therefore, clinical guidelines recommend that psychotherapy should be used for the initial treatment of PTSD in children and adolescents.¹⁶

Since the 1990s, psychotherapies have been increasingly applied in the treatment of PTSD in children and adolescents, and the evidence on their efficacy has been reported encouraging in recent reviews.¹⁷⁻¹⁹ Many types of psychotherapies are now available, such as cognitive behavioral therapy (CBT), eye movement desensitization and

1
2
3 reprocessing (EMDR), behavioral therapy (BT), cognitive therapy, psychodynamic therapy and play therapy. Among
4 these, trauma-focused CBT (TF-CBT), a CBT program that utilises cognitive-behavioral techniques with a
5 trauma-focused component, is the most commonly practiced psychotherapy for children and adolescents with PTSD.²⁰
6
7 TF-CBT has been recommended as a first-line treatment by clinical guidelines for PTSD in children and adolescents.^{16,21}
8
9 However, trauma-focused therapy can be difficult for some therapists to implement,^{22,23} and there are some safety
10 concerns in clinical practice (e.g. symptoms worsening and ending treatment prematurely).^{24,25} Two recent trials that
11 directly compared TF-CBT with non-TF-CBT reported that both of the two treatment modalities were efficacious.^{23,26}
12
13 Thus, whether the inclusion of a trauma focus component is essential in CBT for PTSD in children and adolescents is still
14 uncertain. Besides, other therapies, such as EMDR and BT, have also been reported effective in treating PTSD symptoms
15 in children and adolescents.^{27,28} However, due to the limited number of randomised controlled trials (RCTs) directly
16 comparing different types of psychotherapies, conventional meta-analyses cannot provide a clear answer regarding the
17 best choice for initial treatment, nor with regard to a hierarchy of these psychotherapies.
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32
33 Network meta-analysis is a newly developed method for evidence synthesis, which is able to integrate direct
34 evidence (from studies directly comparing interventions) with indirect evidence (derived from separate studies
35 addressing a common reference condition) from multiple treatment comparisons to estimate the interrelations across all
36 treatments.²⁹ This approach enables a simultaneous comparison of multiple treatments without adversely affecting
37 randomisation of treatments within each trial, and can provide hierarchical evidence to guide clinical practice. Using this
38 method, our research group has found a series of important findings among psychotherapies for the treatment of anxiety
39 disorder³⁰ and depressive disorder³¹ in children and adolescents. Therefore, the aim of this paper is to describe the
40 protocol of a Bayesian network meta-analysis that synthesise all the evidence on psychotherapies for PTSD in children
41 and adolescents and provide clinicians with a reliable treatment hierarchy.
42
43
44
45
46
47
48
49
50
51
52
53
54
55

56 METHODS

Criteria for included studies

Types of studies

All randomised controlled trials (RCTs), including cluster-randomised trials and cross-over trials, will be included. However, only the results from the first randomisation period will be considered in the cross-over trials. For the purpose of reducing heterogeneity between trials, we will exclude quasi-randomised trials (e.g., allocation based on the last number of the date of birth) and trials in which the sample size is less than 10 per study. In addition, to decrease the heterogeneity and inconsistency of this network, trials in which the number of sessions is less than four will be excluded.³²

Types of participants

Studies that enrolled children and adolescents, aged 18 years old or less when they were initially enrolled, will be included in this review. Given that children with significant PTSD symptoms who do not meet full criteria for a PTSD diagnosis often have comparable functional impairment to those with a PTSD diagnosis,^{33,34} the clinical guideline suggested that treatment decisions should be based on symptom severity and functional impairment, rather than whether or not they have an actual PTSD diagnosis.¹⁶ Therefore, we will apply the following broad criteria to identify the participants: (1) Full PTSD, as diagnosed according to standardised diagnostic interviews based on international classifications (the Diagnostic and Statistical Manual of Mental Disorders (DSM),^{3,35-38} the International Classification of Diseases (ICD)^{39,40} or validated scales for PTSD based on DSM/ ICD criteria;⁴¹⁻⁴⁴ (2) Subclinical/Partial PTSD, defined as patients who have experienced psychological trauma and report some subsequent PTSD symptoms in at least one of the four symptom clusters according to DSM-5 (i.e., reexperiencing, avoidance, hyperarousal, negative alterations in cognition and mood);⁴⁵ (3) Clinically significant posttraumatic stress symptoms, defined as scoring above a validated cutoff on a PTSD rating scale, such as Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS)⁴², Child PTSD Symptoms Scale (CPSS)⁴⁶ and the Impact of Event Scale (IES)⁴⁷. We will include trials in which participants have

1
2
3 a secondary diagnosis of comorbid general psychiatric disorders, e.g., depressive disorder, anxiety disorder, attention
4 deficit hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD). However, trials in which participants
5
6 have a diagnosis of acute stress disorder (ASD) or adjustment disorder (AD) will be excluded. Studies where both adults
7
8 and children/adolescents are included will be eligible for inclusion, if the data for the latter can be obtained separately.
9
10
11
12
13 Trials conducted in any treatment settings, including outpatient clinics, inpatient services, community clinics and schools
14
15 will be included.
16

17 ***Types of interventions***

18
19 All RCTs comparing any structured psychotherapy against another structured psychotherapy or any control
20
21 condition for children and adolescents with PTSD will be included. We will view each of: trauma-focused CBT
22
23 (TF-CBT), non-trauma-focused CBT (Non-TF-CBT), eye movement desensitization and reprocessing (EMDR),
24
25 behavioral therapy (BT), cognitive therapy (CT), psychodynamic therapy (DYN), play therapy (PT), and any other
26
27 structured psychotherapy as independent nodes in this network meta-analysis. Trials comparing the same type of
28
29 psychotherapies, but at different delivery conditions (with or without family involvement), different delivery formats
30
31 (group, individual, or group plus individual) and different delivery mediums (face-to-face, internet-based) will be
32
33 considered as the same node in this network meta-analysis. Nevertheless, because TF-CBT is the most commonly studied
34
35 psychotherapy and recommended by clinical guidelines as first-line choice for children and adolescents with PTSD,^{16,21} if
36
37 data available, we will separate TF-CBT with different delivery conditions, formats, and mediums as independent nodes.
38
39

40
41 Control conditions can include supportive therapy (ST), waitlist (WL), non-treatment (NT), and treatment as usual
42
43 (TAU). We will view each of these control conditions as independent nodes in this network meta-analysis. The detailed
44
45 description of each treatment and control condition are presented in Table 1.
46
47
48
49

50
51 Studies where psychotherapy is used as a combination strategy (e.g., combining psychotherapy with medication)
52
53 will be excluded, because such designs make it impossible for us to detect effect size of each specific treatment approach.
54
55
56

Types of outcome measures

Primary outcome

1. Efficacy at post-treatment, as measured using the end point score from PTSD symptom severity rating scales completed by the child, parent, or a clinician.⁴⁸ When end point scores are not reported, we will use change scores (if available).⁴⁹ Where more than one scale is reported in a trial, we will extract data from the PTSD symptom scales on a hierarchy, which is based on psychometric properties and appropriateness for use with children and adolescents (Table 2). In addition, where a PTSD symptom scale is reported by different raters in a trial, self-rated outcome will be preferred, then the parent or clinician rated outcome, because self-rated outcome tends to result in conservative effect sizes.⁵⁰

Secondary outcomes

1. Efficacy at follow-up, as measured by the score from PTSD scales at the longest point of follow-up (up to 12 months). The selection priority of PTSD scales will be the same as for efficacy at post-treatment. Data from participants who take part in subsequent treatments (e.g., continuing psychotherapy/pharmacotherapy or booster sessions) will be excluded in the follow-up analysis.

2. Acceptability, defined as all-cause discontinuation, as measured by the proportion of patients who discontinued treatment for any cause at the end of treatment. Notably, children and adolescents may discontinue treatment for many different reasons, such as finding it difficult to adhere to long-term treatment, because symptoms worsen, or due to rapid improvement of symptoms.³⁰

3. Anxiety symptoms, as measured by the end point score on anxiety symptom severity rating scales. The following scales will be used: Revised Children's Manifest Anxiety Scale (RCMAS), Spence Children's Anxiety Scale (SCAS), Multidimensional Anxiety Scale for Children (MASC), State-Trait Anxiety Inventory for Children (STAIC), Screen for Anxiety and Related Disorders (SCARED). If none of above scales are reported, other valid anxiety scales will be used. When a scale is reported by different raters in a trial, self-rated outcome will be preferred.

4. Depressive symptoms, as measured by the end point score on depressive symptom severity rating scales, The

1
2
3 following scales will used: Children's Depression Inventory (CDI), Beck depression inventory (BDI), Mood and Feeling
4
5
6 Questionnaire (MFQ), Children's Depression Rating Scale Revised (CDRS-R), Hamilton Depression Rating Scale
7
8 (HAMD). As for anxiety, other valid depression scales will be used if none of the above scales were reported.
9

10
11 5. Quality of life and functional improvement (QoL/functioning). If data are available, we will extract continuous
12
13 outcomes from scales of quality of life and functional improvement measured at post-treatment. The scales of quality of
14
15 life include Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), Pediatric Quality of Life Inventory
16
17 (QoL Child Report), the Quality of Life Inventory (QoLI), and others. The scales of functional improvement include the
18
19 Children's Global Assessment Scale (CGAS), the Global Assessment Functioning (GAF), and others. When both of the
20
21 scales of quality of life and functional improvement are reported in a trial, we will extract the data of quality of life.
22
23
24

25 ***Search strategy***

26
27
28 We will identify relevant trials from systematic searches in the following electronic databases: PubMed, Cochrane,
29
30 EMBASE, Web of Science, PsycINFO, CINAHL, PILOTS and ProQuest Dissertations. The timeline will be from
31
32 database inception to October 2017. The following search strategy with filters of clinical study will be applied: Condition
33
34 = [(post-traumatic* or PTSD or PTSS or posttrauma* or trauma* or peritrauma* or peri-trauma* or psychotraumatology
35
36 or "stress disorder*" or "stress reactions" or "sexually abus*" or "sexual abus*" or "sexually assault*" or "sexual
37
38 assault*" or "physical abuse*" or "physically abuse*" or "child abuse" or "children abuse" or "natural disaster" or
39
40 refugee or war or violence or maltreat* or mistreat or acciden* or tsunامي* or hurricane* or earthquake or tornado)]
41
42
43 AND Intervention = ("trauma focused" or trauma-specific or cogniti* or behavio* or CBT or "eye movement
44
45 desensitization and reprocessing" or EMDR or EMD or "stress management" or "stress inoculation training" or
46
47 mindfulness or "art therapy" or "play therapy" or hypnotherapy or biofeedback or counsel* or supportive or interpersonal
48
49 or bibliotherapy or narrative or narration or exposure* or psychoeducation or "family treatment" or "family therapy" or
50
51 meditation or relaxation or "problem solving" or "school-based intervention" or "school-based treatment" or "mind-body
52
53
54
55
56
57

1
2
3 skills" or "seeking safety" or "mental health" or "writing for recovery" or "psychosocial intervention" or "child centered"
4
5 or psychodynamic or psychodrama or desensitization or psychological or psychotherap*) AND Age = (adolesc* or boy*
6
7 or girl* or child* or infant* or juvenil* or minors or pediatri* or paediatric* or pubescen* or puberty or student* or teen*
8
9 or young or youth* or school* or high-school or preschool* or pre-school* or class*). The following Medical Subject
10
11 Headings (MeSH) will also be searched: "Stress Disorders" AND "Psychotherapy" AND ("child" OR "adolescent"). In
12
13 addition, international trials registers, such as World Health Organization's trials portal, ClinicalTrials.gov and Australian
14
15 New Zealand Clinical Trials Registry (ANZCTR) will be searched for ongoing trials. Furthermore, we will hand-search
16
17 relevant key psychiatric and medical journals (including *Behavior Therapy*, *Child Abuse and Neglect*, *Child*
18
19 *Maltreatment*, *Journal of Counseling and Development*, *Counseling Outcome Research and Evaluation*, *Journal of*
20
21 *Anxiety Disorders*, *Journal of Mental Health Counseling*, *Journal of Trauma Practice*, *Journal of Traumatic Stress*,
22
23 *Journal of the American Academy of Child and Adolescent Psychiatry*). The reference lists of included trials and reviews
24
25 identified from initial searches will be scanned for more relevant studies. All relevant authors will be contacted to
26
27 complement the incomplete data.

28 **Study selection and data extraction**

29 ***Selection of trials***

30
31 Two reviewers (YZ and LY) will independently identify potentially eligible studies from the titles and abstracts of
32
33 records from the search strategies. Studies will be excluded if both reviewers consider that it does not meet eligibility
34
35 criteria. Then, the full texts of these potentially eligible studies will be reviewed by the same criteria. The inter-rater
36
37 reliability of the two reviewers will be calculated to detect their consistency. All disagreements will be discussed and
38
39 resolved by a senior review author (PX or SEH). The references of relevant reviews and included trials will be checked
40
41 by YZ and LY. Where multiple publications derive from a common data set, we will select the trials in which the relevant
42
43 outcomes we predefined in this protocol were reported completely. We will report the reasons for exclusion for each trial
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 in the characteristics of excluded studies list. Finally, a flow chart will be used to present the process of trial screening in
4
5
6 this meta-analysis.

7 8 ***Risk of bias assessment*** 9

10 Two reviewers (YZ and XZ) will independently assess the methodological quality of the included studies.
11
12 According to the Cochrane Collaboration's Risk of bias' 2.0 tool,⁵¹ the risk of bias will be rated as "low risk", "high risk",
13
14 or "some concerns" in the following domains: (1) bias arising from the randomization process, (2) bias due to deviations
15
16 from intended interventions, (3) bias due to missing outcome data, (4) bias in measurement of the outcome, (5) bias in
17
18 selection of the reported result, (6) overall bias. The inter-rater reliability of the two reviewers assessing the risk of bias
19
20 will also be calculated. Any disagreements will be resolved by a senior review author (PX or SEH).
21
22
23
24

25 26 ***Data extraction*** 27

28 A standardised data extraction form will be used by two independent reviewers (YZ and XZ) to record the relevant
29
30 parameters from the original paper, including study characteristics (e.g., title, first author, publication year, publication
31
32 type, publication journal, location, and sponsor), patient characteristics (e.g., diagnostic criteria for PTSD, type of trauma,
33
34 severity of PTSD symptoms, comorbidities, and the number, mean age and gender of participants), intervention details
35
36 (e.g., type of psychotherapy, treatment format, treatment setting, treatment duration, the number of sessions, follow-up
37
38 duration, and co-interventions) and outcome measures (mean scores, number of participants, and outcome raters for each
39
40 pre-defined outcome). A table will be used to present the main characteristics of each study included in this review. The
41
42 reliability of data extraction from the reviewers will also be assessed. Any disagreements will be resolved by a senior
43
44 review author (PX or SEH).
45
46
47
48

49 50 ***Statistical analysis*** 51

52 We will perform Bayesian network meta-analysis for each outcome with random-effects model in WinBUGS
53
54 (version 1.4.3). In addition, as a reference for relative outcomes of network meta-analyses, conventional pairwise
55
56

1
2
3 meta-analyses will also be performed for each outcome with a random-effects model in Stata (version 13.0). Standardised
4
5 mean difference (SMD, Cohen's d) will be used as a measure of effect size where outcome is measured on different
6
7 scales. For dichotomous outcomes, the effect sizes will be calculated as odds ratios (OR). Statistical heterogeneity in
8
9 each pairwise comparison will be assessed with the I^2 statistic and p value.⁵² When the mean values or SDs of relative
10
11 outcomes are missing, we will obtain such value by conversion from p-values, t-values, confidence intervals or standard
12
13 errors.⁵³ Missing continuous outcome data will be analysed using the completer data.

14
15
16
17
18 The pooled estimates of network meta-analysis will be obtained using the Markov Chains Monte Carlo method. Two
19
20 Markov chains will be run simultaneously with different arbitrarily chosen initial values. Trace plots and the
21
22 Brooks-Gelman-Rubin statistic will be monitored to ensure convergence.⁵⁴ When the model is adequately convergent, the
23
24 foregoing samples will be discarded. Then 100,000 subsequent simulations will be run as the posterior summaries. All
25
26 results will be reported as effect sizes (SMD or OR) and their 95% credible intervals (CrI). We will assume a common
27
28 heterogeneity parameter for each comparison and assess the global heterogeneity using the I^2 statistic with 'gemtc'
29
30 package in R (version 3.2.2). Furthermore, the inconsistency between direct and indirect evidence will be evaluated,
31
32 which will include the assessment of global inconsistency (by comparing the fit and parsimony of consistency and
33
34 inconsistency models), local inconsistency (by calculating the difference among direct and indirect evidence in closed
35
36 loops in the network)⁵⁵ and the inconsistency calculated by node splitting method (by assessing the difference between
37
38 direct and indirect estimates within a particular comparison).⁵⁶ Probability values will be summarised and reported as
39
40 surface under the cumulative ranking curve (SUCRA) to provide a hierarchy of the treatments.⁵⁷

41 42 43 44 45 46 47 ***Subgroup analysis***

48
49
50 Where possible, we will conduct network meta-regression of data on primary outcome, to evaluate the influence of
51
52 the following potential moderators: (1) age group; (2) sex ratio; (3) number of sessions; (4) sample size; (5) risk of bias;
53
54 (6) trauma types (acute/single trauma vs chronic trauma); (7) diagnosis criteria (youth with a diagnosis vs with
55
56

1
2
3 subsyndromal symptoms); (8) source of outcome measure (self-rated vs observer-rated). If the data are insufficient to
4
5
6 conduct subgroup analyses for some moderators, we will perform sensitivity analyses by omitting specific trials from the
7
8 overall analysis.
9

10 ***Other analyses***

11
12
13 Comparison-adjusted funnel plots and Egger's test will be used for each outcome to examine whether there is
14
15 dominant publication bias exist in this network meta-analysis.⁵⁶ In addition, we will evaluate the quality of evidence for
16
17 primary outcome by using the GRADE framework, which characterises the quality of a body of evidence on the basis of
18
19 the study limitations, imprecision, inconsistency, indirectness, and publication bias for network estimates.⁵⁸
20
21
22

23 **Ethics and dissemination**

24
25 This network meta-analysis will use data in the public domain. Therefore, no formal ethical assessment and
26
27 informed consent are required. The results will be published in a peer-reviewed journal and disseminated electronically
28
29 and in print.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Contributors

PX, YZ and XZ conceived the study and drafted the manuscript. SEH, JRW, PC, JB, CDG, DC, DG assisted in protocol design and revision. YZ, XZ, LY, SY, XJ, and TT participated in the search strategy development, and will carry out the most work of study selection, risk of bias assessment, and data collection. PX, and SEH will help to resolve the disagreements and check the data. CDG, YZ and XZ participated in the design of data synthesis and analysis, and will conduct the statistical analyses. All the authors have approved the publication of the protocol.

Funding This work is supported by National Key Research and Development Programm of China (Grant No.2017YFA0505700). The funders had no role in the protocol design; the writing of the protocol; or the decision to submit the protocol for publication.

Competing interests SEH is an editor of the Cochrane Common Mental Disorders Group, and an author on the Cochrane systematic review on treatments for PTSD in young people. During the last two years, David Cohen reported past consultation for or the receipt of honoraria from Otsuka, Shire, Lundbeck and Roche. DG is the primary author of two reviews of psychological therapies for children and adolescents who were diagnosed with PTSD or exposed to trauma. YZ, XZ, LY, JRW, PC, JB, CDG, SY, XJ, TT, and PX declare no competing interests.

Provenance and peer review Not commissioned; externally peer-reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution- Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

- 1 Copeland WE, Keeler G, Angold A, et al. Traumatic events and post-traumatic stress in childhood. *Arch General Psychiatry* 2007;64:577-84.
- 2 Alisic E, Zalta AK, Van Wesel F, et al. Rates of post-traumatic stress disorder in trauma-exposed children and adolescents: meta-analysis. *Br J Psychiatry* 2014;204:335-40
- 3 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edn. Arlington, VA: American Psychiatric Publishing, 2013.
- 4 Donnelly CL, Amaya-Jackson L. Post-traumatic stress disorder in children and adolescents: epidemiology, diagnosis and treatment options. *Paediatr Drugs* 2002;4:159-70.
- 5 Taylor TL, Chemtob CM. Efficacy of treatment for child and adolescent traumatic stress. *Arch Pediatr Adolesc Med* 2004;158:786-91.
- 6 Dorsey S, McLaughlin KA, Kerns SEU, et al. Evidence Base Update for Psychosocial Treatments for Children and Adolescents Exposed to Traumatic Events. *J Clin Child Adolesc Psychol* 2017;46:303-30.
- 7 De Bellis MD, Hooper SR, Woolley DP, et al. Demographic, maltreatment, and neurobiological correlates of PTSD symptoms in children and adolescents. *J Pediatr Psychol* 2010;35:570-7.
- 8 Dixon A, Howie P, Starling J. Trauma exposure, posttraumatic stress, and psychiatric comorbidity in female juvenile offenders. *J Am Acad Child Adolesc Psychiatry* 2005;44:798-806.
- 9 Lipschiz D, Rasmussen AM, Anyan W, et al. Posttraumatic stress disorder and substance use in inner city girls. *J Nervous Mental Disease* 2003;191:714-21.
- 10 Ford JD, Racusin R, Ellis CG, et al. Child maltreatment, other trauma exposure and posttraumatic symptomatology among children with oppositional disorder and attention deficit hyperactivity disorders. *Child Maltreat* 2000;5:205-17.
- 11 Gerson R, Rappaport N. Traumatic stress and posttraumatic stress disorder in youth: recent research findings on

- 1
2
3 clinical impact, assessment, and treatment. *J Adolesc Health* 2013;52:137–43.
- 4
5
6 12. Keeshin BR, Strawn JR. Psychological and pharmacologic treatment of youth with posttraumatic stress disorder: an
7
8 evidence-based review. *Child Adolesc Psychiatr Clin N Am* 2014;23:399-411,
9
- 10
11 13. Bajor LA, Ticlea AN, Osser DN. The Psychopharmacology Algorithm Project at the Harvard South Shore Program:
12
13 an update on posttraumatic stress disorder. *Harv Rev Psychiatry* 2011;19:240-58.
- 14
15
16 14. U.S. Food and Drug Administration (FDA). Suicidality in children and adolescents being treated with antidepressant
17
18 medications. [http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/](http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm161679.htm)
19
20 [ucm161679.htm](http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm161679.htm) (accessed 2 Aug 2017).
- 21
22
23 15. Cipriani A, Zhou X, Del Giovane C, et al. Comparative efficacy and tolerability of antidepressants for major
24
25 depressive disorder in children and adolescents: a network meta-analysis. *Lancet* 2016;388:881-90.
- 26
27
28 16. Cohen JA, Bukstein O, Walter H, et al. Practice Parameter for the assessment and treatment of children and
29
30 adolescents with posttraumatic stress disorder. *J Am Acad Child Adolesc Psychiatry* 2010;49:414–30.
- 31
32
33 17. Gillies D, Taylor F, Gray C, et al. Psychological therapies for the treatment of post-traumatic stress disorder in
34
35 children and adolescents. *Cochrane Database Syst Rev* 2012;12:CD006726.
- 36
37
38 18. Gillies D, Maiocchi L, Bhandari AP, et al. Psychological therapies for children and adolescents exposed to trauma.
39
40 *Cochrane Database Syst Rev* 2016;10:CD012371.
- 41
42
43 19. Gutermann J, Schreiber F, Matulis S, et al. Psychological treatments for symptoms of posttraumatic stress disorder
44
45 in children, adolescents, and young adults: a meta-analysis. *Clin Child Fam Psychol Rev* 2016;19:77-93.
- 46
47
48 20. Lenz AS, Hollenbaugh KM. Meta-analysis of trauma-focused cognitive behavioral therapy for treating PTSD and
49
50 co-occurring depression among children and adolescents. *Counseling Outcome Research and Evaluation*
51
52 2015;6:18-32.
- 53
54
55 21. National Collaborating Centre for Mental Health (NCCMH). Post-traumatic stress disorder: The management of
56
57

- 1
2
3 PTSD in adults and children in primary and secondary care. National Clinical Practice Guideline Number 26.
4
5
6 London: National Institute for Clinical Excellence (NICE), 2005.
7
- 8 22. Cohen J, Mannarino AP, Deblinger E. Treating Trauma and Traumatic Grief in Children and Adolescents. New York:
9
10 Guilford; 2006.
11
- 12 23. Salloum A, Overstreet S. Grief and trauma intervention for children after disaster: exploring coping skills versus
13
14 trauma narration. *Behav Res Ther* 2012;50:169-79.
15
- 16 24. Linden M, Schermuly-Haupt ML. Definition, assessment and rate of psychotherapy side effects. *World Psychiatry*
17
18 2014;13:306-9.
19
- 20 25. Nutt DJ, Sharpe M. Uncritical positive regard? Issues in the efficacy and safety of psychotherapy. *J*
21
22 *Psychopharmacol* 2008;22:3-6.
23
- 24 26. Deblinger E, Mannarino AP, Cohen JA, et al. Trauma-focused cognitive behavioral therapy for children: impact of
25
26 the trauma narrative and treatment length. *Depress Anxiety* 2011;28:67-75.
27
- 28 27. Ahmad A, Larsson B, Sundelin-Wahlsten V. EMDR treatment for children with PTSD: results of a randomized
29
30 controlled trial. *Nord J Psychiatry* 2007;61:349-54.
31
- 32 28. Ruf M, Schauer M, Neuner F, et al. Narrative exposure therapy for 7- to 16-year-olds: A randomized controlled trial
33
34 with traumatized refugee children. *J Trauma Stress* 2010;23:437-45.
35
- 36 29. Mavridis D, Giannatsi M, Cipriani A, et al. A primer on network meta-analysis with emphasis on mental health.
37
38 *Evid Based Ment Health* 2015;18:40-6.
39
- 40 30. Zhang Y, Zhou X, James AC, et al. Comparative efficacy and acceptability of psychotherapies for acute anxiety
41
42 disorders in children and adolescents: study protocol for a network meta-analysis. *BMJ Open* 2015;5:e008572.
43
- 44 31. Zhou X, Hetrick SE, Cuijpers P, et al. Comparative efficacy and acceptability of psychotherapies for depression in
45
46 children and adolescents: a systematic review and network meta-analysis. *World Psychiatry* 2015;14:207-22.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 32. National Collaborating Centre for Mental Health (UK). Post-traumatic stress disorder: The management of PTSD in
5
6 adults and children in primary and secondary care. Gaskell, 2005.
7
- 8
9 33. Carrion VG, Weems CF, Ray R, et al. Toward an empirical definition of pediatric PTSD: the phenomenology of
10
11 PTSD in youth. *J Am Acad Child Adolesc Psychiatry* 2002;41:166-73.
12
- 13
14 34. Scheeringa M, Zeanah C, Myers L, et al. Predictive validity in a prospective follow-up of PTSD in preschool
15
16 children. *J Am Acad Child Adolesc Psychiatry* 2005;44:899-906.
17
- 18
19 35. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders (DSM-III). 3rd edn.
20
21 Washington DC: American Psychiatric Association, 1980.
22
- 23
24 36. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders (DSM-III-R). 3rd
25
26 revised edn. Washington DC: American Psychiatric Association, 1987.
27
- 28
29 37. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders (DSM-IV). 4th edn.
30
31 Washington DC: American Psychiatric Association, 1994.
32
- 33
34 38. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders (DSM-IV-TR). 4th
35
36 edn. Washington DC: American Psychiatric Association, 2000.
37
- 38
39 39. World Health Organization (WHO). The ninth revision of the international classification of diseases and related
40
41 health problems (ICD-9). Geneva: World Health Organization, 1978.
42
- 43
44 40. World Health Organization (WHO). The tenth revision of the international classification of diseases and related
45
46 health problems (ICD-10). Geneva: World Health Organization, 1992.
47
- 48
49 41. Nader KO, Newman E, Weathers FW, et al. Clinician-Administered PTSD scale for children and adolescents for
50
51 DSM-IV (CAPS-CA). Los Angeles, USA: National Center for PTSD & UCLA Trauma Psychiatry Program
52
53 collaboration, 1998.
54
- 55
56 42. Pynoos RS, Rodriguez N, Steinberg A, et al. The UCLA PTSD Reaction Index for DSM-IV (Revision 1). Los
57
58
59
60

- 1
2
3 Angeles: UCLA Trauma Psychiatry Program, 1998.
4
5
6 43. Kaufman J, Birmaher B, Brent DA, et al. Schedule for affective disorders and schizophrenia for school-aged
7
8 children: present and lifetime version (K-SADS-PL): initial reliability and validity data. *J Am Acad Child Adolesc*
9
10 *Psychiatry* 1996;36:980–88.
11
12
13 44. Silverman WK, Albano AM. Anxiety Disorders Interview Schedule for DSM-IV: child and parent versions. San
14
15 Antonio, TX: Psychological Corporation, 1996.
16
17
18 45. Franklin CL, Piazza V, Chelminski I, et al. Defining subthreshold PTSD in the DSM-IV literature: a look toward
19
20 DSM-5. *J Nerv Ment Dis* 2015;203:574-7.
21
22
23 46. Foa EB, Johnson KM, Feeny NC, et al. The child PTSD symptom scale: a preliminary examination of its
24
25 psychometric properties. *J Clin Child Psychol* 2001;30:376-84.
26
27
28 47. Horowitz M, Wilner N, Alvarez W. Impact of event scale: a measure of subjective stress. *Psychosom Med*
29
30 1979;41:209–18.
31
32
33 48. Cuijpers P, Weitz E, Cristea IA, Twisk J. Pre-post effect sizes should be avoided in meta-analyses. *Epidemiol*
34
35 *Psychiatr Sci* 2017;26:364-8.
36
37
38 49. da Costa BR, Nüesch E, Rutjes AW, et al. Combining follow-up and change data is valid in meta-analyses of
39
40 continuous outcomes: a meta-epidemiological study. *J Clin Epidemiol* 2013;66:847–55.
41
42
43 50. Cuijpers P, Li J, Hofmann SG, et al. Self-reported versus clinician-rated symptoms of depression as outcome
44
45 measures in psychotherapy research on depression: a meta-analysis. *Clin Psychol Rev* 2010;30:768–78.
46
47
48 51. Higgins JPT, Sterne JAC, Savović J, et al. A revised tool for assessing risk of bias in randomized trials In: Chandler
49
50 J, McKenzie J, Boutron I, Welch V (editors). *Cochrane Methods*. Cochrane Database of Systematic Reviews 2016,
51
52 Issue 10 (Suppl 1). dx.doi.org/10.1002/14651858.CD201601
53
54
55 52. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60.
56
57
58
59
60

- 1
2
3
4 53. Furukawa TA, Barbui C, Cipriani A, et al. Imputing missing standard deviations in meta-analyses can provide
5
6 accurate results. *J Clin Epidemiol* 2006;59:7–10.
7
8
9 54. Brooks SP, Gelman A. Alternative methods for monitoring convergence of iterative simulations. *J Comput Graph*
10
11 *Stat* 1998;7:434–45.
12
13 55. Chaimani A, Higgins JP, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. *PLoS One*
14
15 2013;8:e76654.
16
17
18 56. Dias S, Welton NJ, Caldwell DM, et al. Checking consistency in mixed treatment comparison meta-analysis. *Stat*
19
20 *Med* 2010;29:932–44.
21
22
23 57. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from
24
25 multiple-treatment meta-analysis: an overview and tutorial. *J Clin Epidemiol* 2011;64:163–71.
26
27
28 58. Salanti G, Del Giovane C, Chaimani A, et al. Evaluating the quality of evidence from a network meta-analysis.
29
30 *PLoS One* 2014;9:e99682.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tables

Table 1 Description of Psychotherapeutic interventions and control condition

Interventions	Abbreviation	Description
<i>Psychotherapeutic Intervention:</i>		
Trauma-focused cognitive-behavioral therapy	TF-CBT	CBT is a combination of cognitive and behavioral techniques. It also involves additional techniques such as relaxation training, affective modulation skills, and enhancement of future safety and development. TF-CBT is a CBT program that involves a trauma focus, which is usually performed through exposure or cognitive processing of thoughts related to the trauma.
Non-trauma-focused cognitive-behavioral therapy	Non-TF-CBT	Non-TF-CBT is a CBT program that focuses on teaching skills for the reduction of anxiety. These treatments utilise procedures that directly target the person's beliefs and behaviors rather than the discussions of specific traumas.
Cognitive therapy	CT	CT mainly uses cognitive restructuring training, which aims at examining youths' automatic thoughts and core schemas and evaluating the accuracy and affective consequences of their views. They aim to teach youths to engage in "rational" thinking about themselves, the traumatic incident, and the world.
Behavioral therapy	BT	BT uses some form of behavioral training, especially for exposure -based therapy and narrative therapy, to help youth reduce trauma-related symptoms. BT is based on principles of habituation.
Eye movement desensitization and reprocessing	EMDR	EMDR aims to help a person reprocess their memories of a traumatic event. The therapy involves bringing distressing trauma-related images, beliefs, and bodily sensations to mind.
Psychodynamic therapy	DYN	Psychodynamic psychotherapy focuses on integrating the traumatic experience into the life experience of the individual as a whole. Childhood issues are often felt to be important.
Play therapy	PT	PT used techniques to engage participants in recreational activities to help them cope with their problems and fears.
Stress management	SM	SM mainly includes some form of relaxation or biofeedback
<i>Control conditions:</i>		
Supportive therapy	ST	ST is an unstructured therapy without specific psychological techniques that it helped people to ventilate their experiences and emotions and offering empathy. e.g. supportive counseling, attention control, minimal contact, active listening, common factor control, nonspecific control
Treatment-as-usual	TAU	TAU is often described as "usual care" or "usual community treatment" in trials, which is not considered to be an unstructured intervention but may have some treatment effects.
Waitlist	WL	WL is a control condition in which the participants receive no active treatment during the study but are informed that they can receive one after the study period is over.
No-treatment	NT	NT is a control condition in which the participants receive no active treatment during the study and in which they do not expect to receive such after the study is over.

Table 2 Hierarchy of PTSD symptom severity measurement scales

Hierarchy	PTSD symptom severity rating scales	Abbreviation
1	UCLA Posttraumatic Stress Disorder Reaction Index	UCLA PTSD Index
2	Child PTSD Symptoms Scale	CPSS
3	Clinician-Administered PTSD Scale/ Clinician Administered PTSD Scale–Child and Adolescent Version	CAPS/ CAPS-CA
4	Impact of Events Scale/ The Children’s Revised Impact of Events Scale	IES/ CRIES
5	Parent report of post-traumatic symptoms/Child report of post-traumatic symptoms	PROPS/CROPS
6	Kiddie-Schedule for Affective Disorders and Schizophrenia	K-SADS
7	Trauma Symptom Checklist for Children	TSCC
8	Posttraumatic Cognitions Inventory/Child post-traumatic cognitions inventory	PTCI/CPTCI
9	Harvard Trauma Questionnaire	HTQ
10	Post traumatic Stress Scale	PSS
11	Child Post-Traumatic Stress-Reaction Index	CPTS-RI
12	The Preschool Age Psychiatric Assessment	PAPA
13	Anxiety Disorders Interview Schedule	ADIS

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Reported on Page #
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Comparative Efficacy and Acceptability of Psychotherapies for Post-traumatic Stress Disorder in Children and Adolescents: Study Protocol for a Systematic Review and Network Meta-Analysis	
Update	1b	None	
Registration	2	PROSPERO CRD42016051786	3
Authors:			
Contact	3a	Yuqing Zhang, Lining Yang, Shuai Yuan, Xiaofeng Jiang, Teng Teng, Peng Xie (Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China) Xinyu Zhou (Department of Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China) Sarah E. Hetrick (Orygen, The National Centre of Excellence in Youth Mental Health, and the Centre of Youth Mental Health, University of Melbourne, Melbourne, Australia) John R. Weisz (Department of Psychology, Harvard University, Cambridge, MA, USA) Pim Cuijpers (Department of Clinical, Neuro and Developmental Psychology, Amsterdam Public Health research institute, VU University Amsterdam, Amsterdam, The Netherlands) Jürgen Barth (Institute for Complementary and Integrative Medicine, University Hospital and University of Zurich, Zurich, Switzerland) Cinzia Del Giovane (Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy) David Cohen (Department of Child and Adolescent Psychiatry, Hôpital Pitié-Salpêtrière, Institut des Systèmes Intelligents et Robotiques, Université Pierre et Marie Curie, Paris, France) Donna Gillies (Western Sydney Local Health District - Mental Health, Westmead, Australia)	1
		Corresponding author :Peng Xie, Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, 1 Youyi Road, Yuzhong District, Chongqing 400016, China; E-mail: xiepeng973@126.com	
Contributions	3b	PX, YZ and XZ conceived the study and drafted the manuscript. SEH, JRW, PC, JB, CDG, DC, DG assisted in protocol design and revision. YZ, XZ, LY, SY, XJ, and TT participated in the search strategy development, and will carry out the most work of study	15

selection, risk of bias assessment, and data collection. PX, and SEH will help to resolve the disagreements and check the data. CDG, YZ and XZ participated in the design of data synthesis and analysis, and will conduct the statistical analyses. All the authors have approved the publication of the protocol.

Amendments	4	None	
Support:			
Sources	5a	None	
Sponsor	5b	This work is supported by National Key Research and Development Programm of China (Grant No.2017YFA0505700).	15
Role of sponsor or funder	5c	The funders had no role in the protocol design; the writing of the protocol; or the decision to submit the protocol for publication.	15

INTRODUCTION

Rationale	6	Trauma is common in children and adolescents. More than two thirds of young people have suffered at least one traumatic event, with approximately 15.9% of whom go on to develop post-traumatic stress disorder (PTSD). If children and adolescents do not receive adequate intervention, the symptoms of PTSD may be long-lasting, and have deleterious effects on well-being later in life. Several forms of interventions have been applied to address PTSD symptoms in children and adolescents, from which psychotherapy is the mainstay of treatment. Since the 1990s, psychotherapies have been increasingly applied in the treatment of PTSD in children and adolescents, and the evidence on their efficacy has been reported encouraging in recent reviews. Many types of psychotherapies are now available, such as cognitive behavioral therapy (CBT), eye movement desensitization and reprocessing (EMDR), behavioral therapy (BT), cognitive therapy, psychodynamic therapy and play therapy. Among these, trauma-focused CBT (TF-CBT), a CBT program that utilises cognitive-behavioral techniques with a trauma-focused component, is the most commonly practiced psychotherapy for children and adolescents with PTSD. TF-CBT has been recommended as a first-line treatment by clinical guidelines for PTSD in children and adolescents. However, trauma-focused therapy can be difficult for some therapists to implement, and there are some safety concerns in clinical practice (e.g. symptoms worsening and ending treatment prematurely). Two recent trials that directly compared TF-CBT with non-TF-CBT reported that both of the two treatment modalities were efficacious. Thus, whether the inclusion of a trauma focus component is essential in CBT for PTSD in children and adolescents is still uncertain. Besides, other therapies, such as EMDR and BT, have also been reported effective in treating PTSD symptoms in children and adolescents. However, due to the limited number of randomised controlled trials (RCTs) directly comparing different types of psychotherapies, conventional meta-analyses cannot provide a clear answer regarding the best choice for initial treatment, nor with regard to a hierarchy of these psychotherapies.	5-6
Objectives	7	The aim of this paper is to describe the protocol of a Bayesian network meta-analysis that synthesise all the evidence on psychotherapies for PTSD in children and adolescents and provide clinicians with a reliable treatment hierarchy	6

METHODS

Eligibility criteria	8	Types of studies All randomised controlled trials (RCTs), including cluster-randomised trials and cross-over trials, will be included. However, only the results from the first randomisation period will be considered in the cross-over trials. For the purpose of reducing heterogeneity between trials, we will exclude quasi-randomised trials (e.g., allocation based on the last number of the date of birth) and trials in	7-8
----------------------	---	--	-----

which the sample size is less than 10 per study. In addition, to decrease the heterogeneity and inconsistency of this network, trials in which the number of sessions is less than four will be excluded.

Types of participants

Studies that enrolled children and adolescents, aged 18 years old or less when they were initially enrolled, will be included in this review. We will apply the following broad criteria to identify the participants: (1) Full PTSD, as diagnosed according to standardised diagnostic interviews based on international classifications (the Diagnostic and Statistical Manual of Mental Disorders (DSM),^{3,35-38} the International Classification of Diseases (ICD)) or validated scales for PTSD based on DSM/ ICD criteria; (2) Subclinical/Partial PTSD, defined as patients who have experienced psychological trauma and report some subsequent PTSD symptoms in at least one of the four symptom clusters according to DSM-5 (i.e., reexperiencing, avoidance, hyperarousal, negative alterations in cognition and mood); (3) Clinically significant posttraumatic stress symptoms, defined as scoring above a validated cutoff on a PTSD rating scale, such as Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS), Child PTSD Symptoms Scale (CPSS) and the Impact of Event Scale (IES). We will include trials in which participants have a secondary diagnosis of comorbid general psychiatric disorders, e.g., depressive disorder, anxiety disorder, attention deficit hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD). However, trials in which participants have a diagnosis of acute stress disorder (ASD) or adjustment disorder (AD) will be excluded. Studies where both adults and children/adolescents are included will be eligible for inclusion, if the data for the latter can be obtained separately. Trials conducted in any treatment settings, including outpatient clinics, inpatient services, community clinics and schools will be included.

Types of interventions

All RCTs comparing any structured psychotherapy against another structured psychotherapy or any control condition for children and adolescents with PTSD will be included. We will view each of: trauma-focused CBT (TF-CBT), non-trauma-focused CBT (Non-TF-CBT), eye movement desensitization and reprocessing (EMDR), behavioral therapy (BT), cognitive therapy (CT), psychodynamic therapy (DYN), play therapy (PT), and any other structured psychotherapy as independent nodes in this network meta-analysis. Trials comparing the same type of psychotherapies, but at different delivery conditions (with or without family involvement), different delivery formats (group, individual, or group plus individual) and different delivery mediums (face-to-face, internet-based) will be considered as the same node in this network meta-analysis. Nevertheless, because TF-CBT is the most commonly studied psychotherapy and recommended by clinical guidelines as first-line choice for children and adolescents with PTSD, if data available, we will separate TF-CBT with different delivery conditions, formats, and mediums as independent nodes. Control conditions can include supportive therapy (ST), waitlist (WL), non-treatment (NT), and treatment as usual (TAU). We will view each of these control conditions as independent nodes in this network meta-analysis. Studies where psychotherapy is used as a combination strategy (e.g., combining psychotherapy with medication) will be excluded, because such designs make it impossible for us to detect effect size of each specific treatment approach.

Information sources	9	We will identify relevant trials from systematic searches in the following electronic databases: PubMed, Cochrane, EMBASE, Web of Science, PsycINFO, CINAHL, PILOTS and ProQuest Dissertations. In addition, international trials registers, such as World Health Organization's trials portal, ClinicalTrials.gov and Australian New Zealand Clinical Trials Registry (ANZCTR) will	10-11
---------------------	---	--	-------

		be searched for ongoing trials. Furthermore, we will hand-search relevant key psychiatric and medical journals (including <i>Behavior Therapy, Child Abuse and Neglect, Child Maltreatment, Journal of Counseling and Development, Counseling Outcome Research and Evaluation, Journal of Anxiety Disorders, Journal of Mental Health Counseling, Journal of Trauma Practice, Journal of Traumatic Stress, Journal of the American Academy of Child and Adolescent Psychiatry</i>). The reference lists of included trials and reviews identified from initial searches will be scanned for more relevant studies.	
Search strategy	10	The following search strategy with filters of clinical study will be applied: Condition = [(post-traumatic* or PTSD or PTSS or posttrauma* or trauma* or peritrauma* or peri-trauma* or psychotraumatology or “stress disorder*” or “stress reactions” or “sexually abus*” or “sexual abus*” or “sexually assault*” or “sexual assault*” or “physical abuse*” or “physically abuse*” or “child abuse” or “children abuse” or “natural disaster” or refugee or war or violence or maltreat* or mistreat or accident* or tsunami* or hurricane* or earthquake or tornado)] AND Intervention = (“trauma focused” or trauma-specific or cogniti* or behavio* or CBT or “eye movement desensitization and reprocessing” or EMDR or EMD or “stress management” or “stress inoculation training” or mindfulness or “art therapy” or “play therapy” or hypnotherapy or biofeedback or counsel* or supportive or interpersonal or bibliotherapy or narrative or narration or exposure* or psychoeducation or “family treatment” or “family therapy” or meditation or relaxation or “problem solving” or “school-based intervention” or “school-based treatment” or “mind-body skills” or “seeking safety” or “mental health” or “writing for recovery” or “psychosocial intervention” or “child centered” or psychodynamic or psychodrama or desensitization or psychological or psychotherap*) AND Age = (adolesc* or boy* or girl* or child* or infant* or juvenil* or minors or pediatri* or paediatric* or pubescen* or puberty or student* or teen* or young or youth* or school* or high-school or preschool* or pre-school* or class*). The following Medical Subject Headings (MeSH) will also be searched: “Stress Disorders” AND “Psychotherapy” AND (“child” OR “adolescent”).	10-11
Study records:			
Data management	11a	We will first manually remove duplicates of initial search results. We will screen citations based on the inclusion and exclusion criteria.	11-12
Selection process	11b	Two reviewers (YZ and LY) will independently identify potentially eligible studies from the titles and abstracts of records from the search strategies. Studies will be excluded if both reviewers consider that it does not meet eligibility criteria. Then, the full texts of these potentially eligible studies will be reviewed by the same criteria. The inter-rater reliability of the two reviewers will be calculated to detect their consistency. All disagreements will be discussed and resolved by a senior review author (PX or SEH). The references of relevant reviews and included trials will be checked by YZ and LY. Where multiple publications derive from a common data set, we will select the trials in which the relevant outcomes we predefined in this protocol were reported completely. We will report the reasons for exclusion for each trial in the characteristics of excluded studies list. Finally, a flow chart will be used to present the process of trial screening in this meta-analysis.	11-12
Data collection process	11c	A standardised data extraction form will be used by two independent reviewers (YZ and XZ) to record the relevant parameters from the original paper. The reliability of data extraction from the reviewers will also be assessed. Any disagreements will be resolved by a senior review author (PX or SEH).	12
Data items	12	Study characteristics (e.g., title, first author, publication year, publication type, publication journal, location, and sponsor), patient characteristics (e.g., diagnostic criteria for PTSD, type of trauma, severity of PTSD symptoms, comorbidities, and the number, mean age and gender of participants), intervention details (e.g., type of psychotherapy, treatment format, treatment setting, treatment duration, the number of sessions, follow-up duration, and co-interventions) and outcome measures (mean scores, number	12

of participants, and outcome raters for each pre-defined outcome). A table will be used to present the main characteristics of each study included in this review.

Outcomes and prioritization	13	<p>Primary outcome</p> <p>1. Efficacy at post-treatment, as measured using the end point score from PTSD symptom severity rating scales completed by the child, parent, or a clinician. When end point scores are not reported, we will use change scores (if available). Where more than one scale is reported in a trial, we will extract data from the PTSD symptom scales on a hierarchy, which is based on psychometric properties and appropriateness for use with children and adolescents (Table 2). In addition, where a PTSD symptom scale is reported by different raters in a trial, self-rated outcome will be preferred, then the parent or clinician rated outcome, because self-rated outcome tends to result in conservative effect sizes.</p> <p>Secondary outcomes</p> <p>1. Efficacy at follow-up, as measured by the score from PTSD scales at the longest point of follow-up (up to 12 months). The selection priority of PTSD scales will be the same as for efficacy at post-treatment. Data from participants who take part in subsequent treatments (e.g., continuing psychotherapy/pharmacotherapy or booster sessions) will be excluded in the follow-up analysis.</p> <p>2. Acceptability, defined as all-cause discontinuation, as measured by the proportion of patients who discontinued treatment for any cause at the end of treatment. Notably, children and adolescents may discontinue treatment for many different reasons, such as finding it difficult to adhere to long-term treatment, because symptoms worsen, or due to rapid improvement of symptoms.³⁰</p> <p>3. Anxiety symptoms, as measured by the end point score on anxiety symptom severity rating scales. The following scales will be used: Revised Children's Manifest Anxiety Scale (RCMAS), Spence Children's Anxiety Scale (SCAS), Multidimensional Anxiety Scale for Children (MASC), State-Trait Anxiety Inventory for Children (STAIC), Screen for Anxiety and Related Disorders (SCARED). If none of above scales are reported, other valid anxiety scales will be used. When a scale is reported by different raters in a trial, self-rated outcome will be preferred.</p> <p>4. Depressive symptoms, as measured by the end point score on depressive symptom severity rating scales, The following scales will be used: Children's Depression Inventory (CDI), Beck depression inventory (BDI), Mood and Feeling Questionnaire (MFQ), Children's Depression Rating Scale Revised (CDRS-R), Hamilton Depression Rating Scale (HAMD). As for anxiety, other valid depression scales will be used if none of the above scales were reported.</p> <p>5. Quality of life and functional improvement (QoL/functioning). If data are available, we will extract continuous outcomes from scales of quality of life and functional improvement measured at post-treatment. The scales of quality of life include Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), Pediatric Quality of Life Inventory (QoL Child Report), the Quality of Life Inventory (QoLI), and others. The scales of functional improvement include the Children's Global Assessment Scale (CGAS), the Global Assessment Functioning (GAF), and others. When both of the scales of quality of life and functional improvement are reported in a trial, we will extract the data of quality of life.</p>	9-10
Risk of bias in individual studies	14	<p>Two reviewers (YZ and XZ) will independently assess the methodological quality of the included studies. According to the Cochrane Collaboration's Risk of bias' 2.0 tool, the risk of bias will be rated as "low risk", "high risk", or "some concerns" in the following domains: (1) bias arising from the randomization process, (2) bias due to deviations from intended interventions, (3) bias due to missing outcome data, (4) bias in measurement of the outcome, (5) bias in selection of the reported result, (6) overall bias.</p> <p>The inter-rater reliability of the two reviewers assessing the risk of bias will also be calculated. Any disagreements will be resolved by a senior review author (PX or SEH).</p>	12

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Data synthesis	15a	We will perform Bayesian network meta-analysis for each outcome with random-effects model in WinBUGS (version 1.4.3). In addition, as a reference for relative outcomes of network meta-analyses, conventional pairwise meta-analyses will also be performed for each outcome with a random-effects model in Stata (version 13.0). Standardised mean difference (SMD, Cohen’s d) will be used as a measure of effect size where outcome is measured on different scales. For dichotomous outcomes, the effect sizes will be calculated as odds ratios (OR). Statistical heterogeneity in each pairwise comparison will be assessed with the I ² statistic and p value. When the mean values or SDs of relative outcomes are missing, we will obtain such value by conversion from p-values, t-values, confidence intervals or standard errors. Missing continuous outcome data will be analysed using the completer data.	12-13
	15b	The pooled estimates of network meta-analysis will be obtained using the Markov Chains Monte Carlo method. Two Markov chains will be run simultaneously with different arbitrarily chosen initial values. Trace plots and the Brooks-Gelman-Rubin statistic will be monitored to ensure convergence. When the model is adequately convergent, the foregoing samples will be discarded. Then 100,000 subsequent simulations will be run as the posterior summaries. All results will be reported as effect sizes (SMD or OR) and their 95% credible intervals (CrI). We will assume a common heterogeneity parameter for each comparison and assess the global heterogeneity using the I ² statistic with ‘gemtc’ package in R (version 3.2.2). Furthermore, the inconsistency between direct and indirect evidence will be evaluated, which will include the assessment of global inconsistency (by comparing the fit and parsimony of consistency and inconsistency models), local inconsistency (by calculating the difference among direct and indirect evidence in closed loops in the network) and the inconsistency calculated by node splitting method (by assessing the difference between direct and indirect estimates within a particular comparison). Probability values will be summarised and reported as surface under the cumulative ranking curve (SUCRA) to provide a hierarchy of the treatments.	13
	15c	Subgroup analysis Where possible, we will conduct network meta-regression of data on primary outcome, to evaluate the influence of the following potential moderators: (1) age group; (2) sex ratio; (3) number of sessions; (4) sample size; (5) risk of bias; (6) trauma types (acute/single trauma vs chronic trauma); (7) diagnosis criteria (youth with a diagnosis vs with subsyndromal symptoms); (8) source of outcome measure (self-rated vs observer-rated). If the data are insufficient to conduct subgroup analyses for some moderators, we will perform sensitivity analyses by omitting specific trials from the overall analysis.	13-14
Meta-bias(es)	16	Comparison-adjusted funnel plots and Egger’s test will be used for each outcome to examine whether there is dominant publication bias exist in this network meta-analysis.	14
Confidence in cumulative evidence	17	We will evaluate the quality of evidence for primary outcome by using the GRADE framework, which characterises the quality of a body of evidence on the basis of the study limitations, imprecision, inconsistency, indirectness, and publication bias for network estimates.	14

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

BMJ Open

Comparative Efficacy and Acceptability of Psychotherapies for Post-traumatic Stress Disorder in Children and Adolescents: Study Protocol for a Systematic Review and Network Meta-Analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020198.R1
Article Type:	Protocol
Date Submitted by the Author:	22-Dec-2017
Complete List of Authors:	Zhang, Yuqing; The First Affiliated Hospital of Chongqing Medical University, Department of Neurology Zhou, Xinyu; The First Affiliated Hospital of Chongqing Medical University, Department of Psychiatry Yang, Lining; The First Affiliated Hospital of Chongqing Medical University, Department of Neurology Hetrick, Sarah; University of Melbourne, Centre for Youth Mental Health; University of Auckland, Department of Psychological Medicine Weisz, John; Harvard University, Department of Psychology Cuijpers, Pim; VU University Amsterdam, Department of Clinical Psychology Barth, Juergen; University Hospital and University of Zurich, Institute for Complementary and Integrative Medicine Del Giovane, Cinzia; University of Bern, Institute of Primary Health Care (BIHAM) Yuan, Shuai; The First Affiliated Hospital of Chongqing Medical University, Department of Neurology Cohen, David; Institut des Systèmes Intelligents et de Robotiques, UPMC Univ Paris 06, Department of Child and Adolescent Psychiatry Gillies, Donna; Western Sydney Local Health District, Mental Health Jiang, Xiaofeng; The First Affiliated Hospital of Chongqing Medical University, Department of Neurology Teng, Teng; The First Affiliated Hospital of Chongqing Medical University, Department of Neurology Xie, Peng; The First Affiliated Hospital of Chongqing Medical University, Department of Neurology; Chongqing Medical University, Institute of Neuroscience and the Collaborative Innovation Center for Brain Science
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Evidence based practice, Pharmacology and therapeutics, Paediatrics
Keywords:	post-traumatic stress disorder, Child & adolescent psychiatry < PSYCHIATRY, psychotherapy, network meta-analysis, systematic review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SCHOLARONE™
Manuscripts

For peer review only

1
2
3 **Comparative Efficacy and Acceptability of Psychotherapies for Post-traumatic Stress Disorder**
4 **in Children and Adolescents: Study Protocol for a Systematic Review and Network**
5 **Meta-Analysis**
6
7
8
9

10 Yuqing Zhang,¹ Xinyu Zhou,² Lining Yang,¹ Sarah E. Hetrick,³ John R. Weisz,⁴ Pim Cuijpers,⁵ Jürgen Barth,⁶ Cinzia Del
11 Giovane,⁷ Shuai Yuan,¹ David Cohen,⁸ Donna Gillies,⁹ Xiaofeng Jiang,¹ Teng Teng,¹ Peng Xie¹
12
13
14
15

16 ¹ Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute
17 of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing,
18 China
19
20

21 ² Department of Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
22

23 ³ Department of Psychological Medicine, University of Auckland, and the Centre of Youth Mental Health, University of
24 Melbourne, Melbourne, Australia
25
26

27 ⁴ Department of Psychology, Harvard University, Cambridge, MA, USA
28

29 ⁵ Department of Clinical, Neuro and Developmental Psychology, Amsterdam Public Health research institute, Vrije
30 Universiteit Amsterdam, The Netherlands
31

32 ⁶ Institute for Complementary and Integrative Medicine, University Hospital and University of Zurich, Zurich,
33 Switzerland
34
35

36 ⁷ Institute of Primary Health Care (BIHAM), University of Bern, Switzerland
37

38 ⁸ Department of Child and Adolescent Psychiatry, Hôpital Pitié-Salpêtrière, Institut des Systèmes Intelligents et
39 Robotiques, Université Pierre et Marie Curie, Paris, France
40

41 ⁹ Western Sydney Local Health District - Mental Health, Westmead, Australia
42
43
44

45 YZ, XZ and LY contributed equally to this work.
46
47
48

49 **Direct correspondence to:**

50 Prof Peng Xie, Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong
51 District, Chongqing, China; E-mail: xiepeng973@126.com.
52
53
54
55

56 Keywords: post-traumatic stress disorder, child, adolescent, psychotherapy, network meta-analysis, systematic review
57
58
59

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Word count: 3333.

For peer review only

ABSTRACT

Introduction: Post-traumatic stress disorder (PTSD) is common among children and adolescents who are exposed to trauma, and it is often associated with significant negative impacts on their psychosocial functioning and quality of life.

Many types of psychotherapies have been found to be effective for PTSD in children and adolescents. However, due to the lack of direct comparisons between different psychotherapies, the hierarchy of treatment efficacy is still unclear.

Therefore, we plan to conduct a systematic review and network meta-analysis to evaluate the efficacy and acceptability of various types of psychotherapies for PTSD in children and adolescents.

Methods and analysis: A systematic search will be conducted among eight electronic databases, including PubMed, Cochrane, EMBASE, Web of Science, PsycINFO, CINAHL, PILOTS and ProQuest Dissertations, from inception to October 2017. Randomised controlled trials (RCTs), regardless of language, publication year, and publication type, comparing any psychotherapies for PTSD to any control condition or alternative treatment in children and adolescents (18 years old or less) diagnosed with full or subclinical PTSD will be included. Study duration and the number of treatment sessions will not be limited. The primary outcome will be PTSD symptom severity at post-treatment as measured by a rating scale reported by the child, parent, or a clinician. The secondary outcomes will include (1) efficacy at follow-up; (2) acceptability (all-cause discontinuation); (3) anxiety symptom severity; (4) depressive symptom severity; and (5) quality of life and functional improvement. Bayesian network meta-analyses for all relative outcome measures will be performed. We will conduct subgroup and sensitivity network meta-analyses to determine whether the findings are affected by study characteristics. The quality of the evidence contributing to network estimates of the primary outcome will be evaluated by the GRADE framework.

Ethics and dissemination: No ethical issues are foreseen. The results will be published in a peer-reviewed journal, which will be disseminated electronically and in print. This network meta-analysis may be updated to inform and guide the clinical management of PTSD in children and adolescents.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Trial registration number: PROSPERO CRD42016051786.

For peer review only

Strengths and limitations of this study

1. Bayesian network meta-analysis can simultaneously compare various types of treatments by integrating all the best evidence (direct and indirect evidence) to estimate the interrelations across all treatments and establish a treatment hierarchy for psychotherapies for post-traumatic stress disorder in children and adolescents.
2. A number of outcomes will be used to comprehensively assess efficacy at post-treatment and follow-up, acceptability, anxiety and depressive symptom severity, quality of life and functional improvement.
3. This study will help to guide clinical decision-making regarding the relative efficacy of various types of psychotherapy, and various delivery modalities, in the treatment of post-traumatic stress disorder in children and adolescents.
4. Subgroup and sensitivity network meta-analyses will help to find potential moderators that affect the efficacy of psychotherapies.
5. The limitations of included studies will be assessed using the Cochrane Collaboration's Risk of bias' 2.0 tool and the quality of evidence for network estimates of the primary outcome will be evaluated by the GRADE framework.

BACKGROUND

Many children and adolescents are exposed to trauma, with more than two thirds reporting at least 1 traumatic event by 16 years of age.¹ Post-traumatic stress disorder (PTSD) is one of the most common mental disorders among children and adolescents who have experienced trauma, with an overall prevalence of 15.9%.² As described in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), PTSD diagnostic criteria includes four symptom clusters: (1) re-experiencing of the traumatic event, (2) avoidance of stimuli associated with the traumatic event, (3) negative alterations in cognition and mood, (4) hyperarousal.³ Trauma exposure is an essential factor in order to be able to diagnose PTSD, which can include physical or sexual abuse, war or terrorism, natural or man-made disasters, witnessing domestic violence, catastrophic illnesses, vehicle or other accidents.^{4,5} PTSD is correlated with various adverse consequences for children and adolescents in cognitive, emotional, social, academic, and other functional domains.⁶ In addition, PTSD commonly co-occurs with other psychiatric conditions, such as major depressive disorder,⁷ anxiety disorder,⁷ substance abuse,⁸ and ADHD.⁹ PTSD diagnosis is accompanied by a significant reduction in quality of life, and it is estimated that successful treatment could save 2.05 quality adjusted life years (QALYs) per child or adolescent with PTSD.¹⁰

Several forms of interventions have been applied to address PTSD symptoms in children and adolescents, from which psychotherapy is the mainstay of treatment.¹¹ Although some medications (e.g., fluoxetine, paroxetine and venlafaxine) have shown a significant but small superiority over placebo (mean effect size=0.23) in PTSD treatment for adults,¹² their use in children and adolescents is still limited because (1) the evidence of the effectiveness of pharmacological treatments for children and adolescents with PTSD is scant,¹³ and, (2) medications have been associated with safety concerns in children and adolescents, including evidence of increased risk of suicidality in children and adolescents treated with antidepressants.^{14,15} Therefore, clinical guidelines recommend that psychotherapy should be used for the initial treatment of PTSD in children and adolescents.¹⁶

1
2
3
4 Since the 1990s, psychotherapies have been increasingly applied in the treatment of PTSD in children and
5
6 adolescents, and recent reviews have reported encouraging results on their efficacy.¹⁷⁻¹⁹ Evidence from Cochrane reviews
7
8 found that psychological therapies are not only effective in preventing PTSD in children and adolescents who have
9
10 undergone trauma, but also effective in treating PTSD in children and adolescents.^{17,18} Many types of psychotherapies are
11
12 now available, such as cognitive behavioral therapy (CBT), eye movement desensitization and reprocessing (EMDR),
13
14 behavioral therapy (BT), cognitive therapy, psychodynamic therapy and play therapy. Among these, trauma-focused CBT
15
16 (TF-CBT), a CBT program that uses cognitive-behavioral techniques with a trauma-focused component, is the most
17
18 commonly practiced psychotherapy for children and adolescents with PTSD.²⁰ TF-CBT has been recommended as a
19
20 first-line treatment by clinical guidelines for PTSD in children and adolescents.^{16,21} However, trauma-focused therapy can
21
22 be difficult for some therapists to implement,^{22,23} and there are some safety concerns in clinical practice (e.g. symptoms
23
24 worsening and patients ending treatment prematurely).^{24,25} Two recent trials that directly compared TF-CBT with
25
26 non-TF-CBT alternatives reported that both were efficacious.^{23,26} Thus, whether the inclusion of a trauma-focused
27
28 component is essential in CBT for PTSD in children and adolescents is still uncertain. Moreover, other therapies, such as
29
30 EMDR and BT, have also been reported effective in treating PTSD symptoms in children and adolescents.^{27,28} However,
31
32 due to methodological limitations, conventional meta-analyses cannot simultaneously compare all these treatments.
33
34 Therefore, they cannot provide a clear answer regarding the best choice for initial treatment, nor can they provide a
35
36 hierarchy of these psychotherapies.
37
38
39
40
41
42
43
44

45 Network meta-analysis is a newly developed method for evidence synthesis, which is able to integrate direct
46
47 evidence (from studies directly comparing interventions) with indirect evidence (derived from separate studies
48
49 addressing a common reference condition) from multiple treatment comparisons to estimate the interrelations across all
50
51 treatments.²⁹ This approach enables a simultaneous comparison of multiple treatments, and can provide hierarchical
52
53 evidence to guide clinical practice. Using this method, our group has produced meta-analyses comparing the effects of
54
55
56
57
58
59
60

1
2
3 different psychotherapies for the treatment of anxiety disorder³⁰ and depressive disorder³¹ in children and adolescents. In
4
5
6 the present study we describe the methods to undertake a network meta-analysis to complement those previous reports
7
8 that will focus on the efficacy of psychotherapies for children and adolescents with PTSD. By performing a
9
10 well-designed Bayesian network meta-analysis, we aim to provide a higher level of evidence that can inform clinical
11
12
13 guidelines for PTSD treatment in young people.
14
15

16 17 **METHODS**

18 19 **Criteria for included studies**

20 21 *Types of studies*

22
23
24 All randomised controlled trials (RCTs), including cluster-randomised trials and cross-over trials, will be included.
25
26
27 However, only the results from the first randomisation period will be considered in the cross-over trials. For the purpose
28
29 of reducing heterogeneity between trials, we will exclude quasi-randomised trials (e.g., allocation based on the last
30
31 number of the date of birth) and trials in which the sample size is less than 10 per study. Study duration and the number
32
33 of treatment sessions will not be limited.
34
35

36 37 *Types of participants*

38
39 Studies that enrolled children and adolescents, aged 18 years old or less when they were initially enrolled, will be
40
41 included in this review. Given that children with significant PTSD symptoms who do not meet full criteria for a PTSD
42
43 diagnosis often have comparable functional impairment to those with a PTSD diagnosis,³²⁻³⁴ the clinical guideline
44
45 suggested that treatment decisions should be based on symptom severity and functional impairment, rather than whether
46
47 or not they have an actual PTSD diagnosis.¹⁶ Therefore, we will apply the following broad criteria to identify the
48
49 participants: (1) Full PTSD, as diagnosed according to standardised diagnostic interviews based on international
50
51 classifications (the Diagnostic and Statistical Manual of Mental Disorders (DSM),^{3,35-38} the International Classification of
52
53 Diseases (ICD)^{39,40}) or validated scales for PTSD based on DSM/ ICD criteria;⁴¹⁻⁴⁴ (2) Subclinical/Partial PTSD, defined
54
55
56
57
58
59
60

1
2
3 as patients who have experienced psychological trauma and report some subsequent PTSD symptoms in at least one of
4
5
6 the four symptom clusters according to DSM-5 (i.e., reexperiencing, avoidance, hyperarousal, negative alterations in
7
8 cognition and mood);⁴⁵ (3) Clinically significant posttraumatic stress symptoms, defined as scoring above a validated
9
10 cutoff on a PTSD rating scale, such as the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS)⁴², Child
11
12 PTSD Symptoms Scale (CPSS)⁴⁶ and the Impact of Event Scale (IES)⁴⁷. We will include trials in which participants have
13
14 a secondary diagnosis of comorbid general psychiatric disorders, e.g., depressive disorder, anxiety disorder, attention
15
16 deficit hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD). However, trials in which participants
17
18 have a diagnosis of acute stress disorder (ASD) or adjustment disorder (AD) will be excluded. Studies where both adults
19
20 and children/adolescents are included will be eligible for inclusion, if the data for the latter can be obtained separately.
21
22
23 Studies where it is not clear what happened to the patients who withdrew from the study will not be excluded, and all
24
25 these patients will be counted as all-cause discontinuation. Trials conducted in any treatment settings, including
26
27 outpatient clinics, inpatient services, community clinics and schools will be included.
28
29
30
31

32 ***Types of interventions***

33
34
35 All RCTs comparing any psychotherapy against another psychotherapy or any control condition for children and
36
37 adolescents with PTSD will be included. We will view each of: trauma-focused CBT (TF-CBT), non-trauma-focused
38
39 CBT (Non-TF-CBT), eye movement desensitization and reprocessing (EMDR), behavioral therapy (BT), cognitive
40
41 therapy (CT), psychodynamic therapy (DYN), play therapy (PT), and any other psychotherapy as independent nodes in
42
43 this network meta-analysis. Trials comparing the same type of psychotherapies, but at different delivery conditions (with
44
45 or without family involvement), different delivery formats (group, individual, or group plus individual) and different
46
47 delivery mediums (face-to-face, internet-based) will be considered as the same node in this network meta-analysis.
48
49
50 Nevertheless, because TF-CBT is the most commonly studied psychotherapy and recommended by clinical guidelines as
51
52 first-line choice for children and adolescents with PTSD,^{16,21} if data available, we will separate TF-CBT with different
53
54
55
56
57
58
59
60

1
2
3 delivery conditions, formats, and mediums as independent nodes.
4

5
6 Control conditions can include waitlist (WL), non-treatment (NT), and treatment as usual (TAU). We will view each
7
8 of these control conditions as independent nodes in this network meta-analysis. The detailed description of each
9
10 treatment and control condition are presented in Table 1. According to the principles described in this table, two
11
12 reviewers will independently perform the classification of all conditions in each trial. Any disagreements will be
13
14 discussed among the review team, and any unclear information will be requested from the relevant authors.
15
16

17
18 Studies where psychotherapy is used as a combination strategy (e.g., combining psychotherapy with medication)
19
20 will be excluded, because such designs make it impossible for us to estimate the effect size of each specific treatment
21
22 approach. We will not exclude studies that enrolled patients who had used medications in the past, provided that their
23
24 medication status was not changed for at least one month prior to study entry and for the study period.
25
26

27 28 *Types of outcome measures*

29 30 *Primary outcome*

31
32 1. Efficacy at post-treatment, as measured using the end point score from PTSD symptom severity rating scales
33
34 completed by the child, parent, or a clinician.⁴⁸ When end point scores are not reported, we will use change scores (if
35
36 available).⁴⁹ Where more than one scale is reported in a trial, we will extract data from the PTSD symptom scales on a
37
38 hierarchy, which is based on psychometric properties and appropriateness for use with children and adolescents (Table 2).
39
40 In addition, where a PTSD symptom scale is reported by different raters in a trial, self-rated outcome will be preferred,
41
42 then the parent or clinician rated outcome, because self-rated outcome tends to result in more conservative effect sizes.⁵⁰
43
44
45
46 Where dichotomous efficacy outcomes, instead of continuous scores, are reported in a trial, we will contact the relevant
47
48 authors to request the data we need. If they don't respond the data will not be used.
49
50

51 52 *Secondary outcomes*

53
54 1. Efficacy at follow-up, as measured by the score from PTSD scales at the longest point of follow-up (up to 12
55
56 months). The selection priority of PTSD scales will be the same as for efficacy at post-treatment. Data from participants
57

1
2
3 who take part in subsequent treatments (e.g., continuing psychotherapy/pharmacotherapy or booster sessions) will be
4
5
6 excluded in the follow-up analysis.
7

8 2. Acceptability, defined as all-cause discontinuation, as measured by the proportion of patients who discontinued
9
10 treatment for any cause at the end of treatment. Notably, children and adolescents may discontinue treatment for many
11
12 different reasons, such as finding it difficult to adhere to long-term treatment, because symptoms worsen, or due to rapid
13
14 improvement of symptoms.³⁰
15
16

17
18 3. Anxiety symptoms, as measured by the end point score on anxiety symptom severity rating scales. The following
19
20 scales will be used: Revised Children's Manifest Anxiety Scale (RCMAS), Spence Children's Anxiety Scale (SCAS),
21
22 Multidimensional Anxiety Scale for Children (MASC), State-Trait Anxiety Inventory for Children (STAIC), Screen for
23
24 Anxiety and Related Disorders (SCARED). If none of above scales are reported, other valid anxiety scales will be used.
25
26
27 When a scale is reported by different raters in a trial, self-rated outcome will be preferred.
28
29

30 4. Depressive symptoms, as measured by the end point score on depressive symptom severity rating scales. The
31
32 following scales will used: Children's Depression Inventory (CDI), Beck depression inventory (BDI), Mood and Feeling
33
34 Questionnaire (MFQ), Children's Depression Rating Scale Revised (CDRS-R), Hamilton Depression Rating Scale
35
36 (HAMD). As for anxiety, other valid depression scales will be used if none of the above scales were reported.
37
38
39

40 5. Quality of life and functional improvement (QoL/functioning). If data are available, we will extract continuous
41
42 outcomes from scales of quality of life and functional improvement measured at post-treatment. The scales of quality of
43
44 life include Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), Pediatric Quality of Life Inventory
45
46 (QoL Child Report), the Quality of Life Inventory (QoLI), and others. The scales of functional improvement include the
47
48 Children's Global Assessment Scale (CGAS), the Global Assessment Functioning (GAF), and others. When scales of
49
50 quality of life and functional improvement are both reported in a trial, we will extract the data of quality of life.
51
52
53

54 ***Search strategy***

55
56
57

We will identify relevant trials from systematic searches in the following electronic databases: PubMed, Cochrane, EMBASE, Web of Science, PsycINFO, CINAHL, PILOTS and ProQuest Dissertations. The timeline will be from database inception to October 2017. The full search strategy for each database is included in the supplementary material. In addition, international trials registers, such as World Health Organization's trials portal, ClinicalTrials.gov and Australian New Zealand Clinical Trials Registry (ANZCTR) will be searched for ongoing trials. Furthermore, we will search the presentations at European Psychiatric Association (EPA), European College of Neuropsychopharmacology (ECNP), American Psychological Association (APA), American Psychiatric Association (APA) and European Society for Child and Adolescent Psychiatry (ESCAP) congresses and hand-search relevant key psychiatric, psychological and medical journals (including *Behavior Therapy*, *Child Abuse and Neglect*, *Child Maltreatment*, *Journal of Counseling and Development*, *Counseling Outcome Research and Evaluation*, *Journal of Anxiety Disorders*, *Journal of Mental Health Counseling*, *Journal of Trauma Practice*, *Journal of Traumatic Stress*, *Journal of the American Academy of Child and Adolescent Psychiatry*, *Journal of Consulting and Clinical Psychology*, *Behaviour research and therapy*). The reference lists of included trials and reviews identified from initial searches will be scanned for more relevant studies. All relevant authors will be contacted to complement the incomplete data.

Study selection and data extraction

Selection of trials

Two reviewers (YZ and LY) will independently identify potentially eligible studies from the titles and abstracts of records from the search strategies. Studies will be excluded if both reviewers consider that it does not meet eligibility criteria. Then, the full texts of these potentially eligible studies will be reviewed by the same criteria. The inter-rater reliability of the two reviewers will be calculated to detect their consistency. All disagreements will be discussed and resolved by a senior review author (PX or SEH). The references of relevant reviews and included trials will be checked by YZ and LY. Where multiple publications derive from a common data set, we will select the trials in which the relevant

1
2
3 outcomes we predefined in this protocol were reported completely. We will report the reasons for exclusion for each trial
4
5
6 in the characteristics of excluded studies list. Finally, a flow chart will be used to present the process of trial screening in
7
8 this meta-analysis.
9

10 ***Risk of bias assessment***

11
12
13 Two reviewers (YZ and XZ) will independently assess the methodological quality of the included studies.
14
15 According to the Cochrane Collaboration's Risk of bias' 2.0 tool,⁵¹ the risk of bias will be rated as "low risk", "high risk",
16
17 or "some concerns" in the following domains: (1) bias arising from the randomization process, (2) bias due to deviations
18
19 from intended interventions, (3) bias due to missing outcome data, (4) bias in measurement of the outcome, (5) bias in
20
21 selection of the reported result, (6) overall bias. The inter-rater reliability of the two reviewers assessing the risk of bias
22
23 will also be calculated. Any disagreements will be resolved by a senior review author (PX or SEH).
24
25
26
27

28 ***Data extraction***

29
30 A standardised data extraction form will be used by two independent reviewers (YZ and XZ) to record the relevant
31
32 parameters from the original paper, including study characteristics (e.g., title, first author, publication year, publication
33
34 type, publication journal, location, and sponsor), patient characteristics (e.g., diagnostic criteria for PTSD, type of trauma,
35
36 severity of PTSD symptoms, comorbidities, and the number, mean age and gender of participants), intervention details
37
38 (e.g., type of psychotherapy, treatment format, treatment setting, treatment duration, the number of sessions, follow-up
39
40 duration, and co-interventions) and outcome measures (mean scores, number of participants, and outcome raters (i.e., self
41
42 rated or observer rated) for each pre-defined outcome). A table will be used to present the main characteristics of each
43
44 study included in this review. The reliability of data extraction from the reviewers will also be assessed. Any
45
46 disagreements will be resolved by a senior review author (PX or SEH).
47
48
49
50
51

52 ***Statistical analysis***

53
54
55 We will perform Bayesian network meta-analysis for each outcome with random-effects model in WinBUGS
56
57

1
2
3 (version 1.4.3). In addition, as a reference for relative outcomes of network meta-analyses, conventional pairwise
4 meta-analyses will also be performed for each outcome with a random-effects model in Stata (version 13.0). Standardised
5
6 mean difference (SMD, Cohen's d) will be used as a measure of effect size where outcome is measured on different
7
8 scales. For dichotomous outcome (all-cause discontinuation), the effect sizes will be calculated as odds ratios (OR).
9
10 Statistical heterogeneity in each pairwise comparison will be assessed with the I^2 statistic and p value.⁵² When the mean
11
12 values or SDs of continuous outcomes are missing, we will compute values by conversion from p-values, t-values,
13
14 confidence intervals or standard errors.⁵³ Missing continuous outcome data will be analysed using completer data.
15
16
17
18
19

20 The pooled estimates of network meta-analysis will be obtained using the Markov Chains Monte Carlo method. Two
21
22 Markov chains will be run simultaneously with different arbitrarily chosen initial values. Trace plots and the
23
24 Brooks-Gelman-Rubin statistic will be monitored to ensure convergence.⁵⁴ When the model is adequately convergent, the
25
26 foregoing samples will be discarded. Then 100,000 subsequent simulations will be run as the posterior summaries. All
27
28 results will be reported as effect sizes (SMD or OR) and their 95% credible intervals (CrI). We will assume a common
29
30 heterogeneity parameter for each comparison and assess the global heterogeneity using the I^2 statistic with 'gemtc'
31
32 package in R (version 3.2.2). Furthermore, the inconsistency between direct and indirect evidence will be evaluated,
33
34 which will include the assessment of global inconsistency (by comparing the fit and parsimony of consistency and
35
36 inconsistency models), local inconsistency (by calculating the difference among direct and indirect evidence in closed
37
38 loops in the network)⁵⁵ and the inconsistency calculated by node splitting method (by assessing the difference between
39
40 direct and indirect estimates within a particular comparison).⁵⁶ Probability values will be summarised and reported as
41
42 surface under the cumulative ranking curve (SUCRA) to provide a hierarchy of the treatments.⁵⁷
43
44
45
46
47
48
49

50 ***Subgroup analysis***

51
52 Where possible, we will conduct network meta-regression of data on primary outcome, to evaluate the influence of
53
54 the following potential moderators: (1) age group; (2) sex ratio; (3) number of sessions; (4) sample size; (5) risk of bias;
55
56
57

1
2
3 (6) trauma types (acute/single trauma vs chronic trauma); (7) diagnosis criteria (youth with a diagnosis vs with
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(6) trauma types (acute/single trauma vs chronic trauma); (7) diagnosis criteria (youth with a diagnosis vs with
subsyndromal symptoms); (8) source of outcome measure (self-rated vs observer-rated). If the data are insufficient to
conduct subgroup analyses for some moderators, we will perform sensitivity analyses by omitting specific trials from the
overall analysis.

Other analyses

Comparison-adjusted funnel plots and Egger's test will be used for each outcome to examine whether there is
dominant publication bias exist in this network meta-analysis.⁵⁶ In addition, we will evaluate the quality of evidence for
primary outcome by using the GRADE framework, which characterises the quality of a body of evidence on the basis of
the study limitations, imprecision, inconsistency, indirectness, and publication bias for network estimates.⁵⁸

Discussion

This systematic review and network meta-analysis will comprehensively evaluate the comparative efficacy and
acceptability of psychological interventions for children and adolescents with PTSD. The results of this research will
provide evidence to inform a hierarchy of comparative efficacy at post-treatment, efficacy with regard to PTSD
symptoms at follow-up, as well as in terms of acceptability (all-cause discontinuation), improvement of anxiety
symptoms, improvement of depressive symptoms, and quality of life and functional improvement. We expect that the
findings could assist patients, clinicians and healthcare providers to make a better-informed choice in treatment selection.

There are some limitations in this protocol. First, due to the fact that PTSD commonly co-occurs with other
psychiatric comorbidities, we will not exclude trials in which patients with comorbidity were enrolled. This will enhance
the generalizability of this study; however, it will also raise the risk of bias for outcomes. Further individual patient data
meta-analysis will be helpful to investigate the influence of this factor. Second, some trials may tend to report their
favourite outcomes. Although we have predefined the data selection criteria for each outcome, this selection bias could
not be completely eliminated.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Ethics and dissemination

This network meta-analysis will use data in the public domain. Therefore, no formal ethical assessment and informed consent are required. The results will be published in a peer-reviewed journal and disseminated electronically and in print.

For peer review only

Contributors

PX, YZ and XZ conceived the study and drafted the manuscript. SEH, JRW, PC, JB, CDG, DC, DG assisted in protocol design and revision. YZ, XZ, LY, SY, XJ, and TT participated in the search strategy development, and will carry out the most work of study selection, risk of bias assessment, and data collection. PX, and SEH will help to resolve the disagreements and check the data. CDG, YZ and XZ participated in the design of data synthesis and analysis, and will conduct the statistical analyses. All the authors have approved the publication of the protocol.

Funding This work is supported by National Key Research and Development Programm of China (Grant No.2017YFA0505700). The funders had no role in the protocol design; the writing of the protocol; or the decision to submit the protocol for publication.

Competing interests SEH is an editor of the Cochrane Common Mental Disorders Group, and an author on the Cochrane systematic review on treatments for PTSD in young people. During the last two years, David Cohen reported past consultation for or the receipt of honoraria from Otsuka, Shire, Lundbeck and Roche. DG is the primary author of two reviews of psychological therapies for children and adolescents who were diagnosed with PTSD or exposed to trauma. YZ, XZ, LY, JRW, PC, JB, CDG, SY, XJ, TT, and PX declare no competing interests.

Provenance and peer review Not commissioned; externally peer-reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution- Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

- 1 Copeland WE, Keeler G, Angold A, et al. Traumatic events and post-traumatic stress in childhood. *Arch General Psychiatry* 2007;64:577-84.
- 2 Alisic E, Zalta AK, Van Wesel F, et al. Rates of post-traumatic stress disorder in trauma-exposed children and adolescents: meta-analysis. *Br J Psychiatry* 2014;204:335-40.
- 3 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edn. Arlington, VA: American Psychiatric Publishing, 2013.
- 4 Donnelly CL, Amaya-Jackson L. Post-traumatic stress disorder in children and adolescents: epidemiology, diagnosis and treatment options. *Paediatr Drugs* 2002;4:159-70.
- 5 Taylor TL, Chemtob CM. Efficacy of treatment for child and adolescent traumatic stress. *Arch Pediatr Adolesc Med* 2004;158:786-91.
- 6 Dorsey S, McLaughlin KA, Kerns SEU, et al. Evidence Base Update for Psychosocial Treatments for Children and Adolescents Exposed to Traumatic Events. *J Clin Child Adolesc Psychol* 2017;46:303-30.
- 7 Dixon A, Howie P, Starling J. Trauma exposure, posttraumatic stress, and psychiatric comorbidity in female juvenile offenders. *J Am Acad Child Adolesc Psychiatry* 2005;44:798-806.
- 8 Lipschiz D, Rasmussen AM, Anyan W, et al. Posttraumatic stress disorder and substance use in inner city girls. *J Nervous Mental Disease* 2003;191:714-21.
- 9 Ford JD, Racusin R, Ellis CG, et al. Child maltreatment, other trauma exposure and posttraumatic symptomatology among children with oppositional disorder and attention deficit hyperactivity disorders. *Child Maltreat* 2000;5:205-17.
- 10 Gospodarevskaya E. Post-traumatic stress disorder and quality of life in sexually abused Australian children. *J Child Sex Abus* 2013;22:277-96.
- 11 Keeshin BR, Strawn JR. Psychological and pharmacologic treatment of youth with posttraumatic stress disorder: an

- evidence-based review. *Child Adolesc Psychiatr Clin N Am* 2014;23:399-411,
12. Hoskins M, Pearce J, Bethell A, et al. Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. *Br J Psychiatry* 2015;206:93-100.
13. Bajor LA, Ticlea AN, Osser DN. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on posttraumatic stress disorder. *Harv Rev Psychiatry* 2011;19:240-58.
14. U.S. Food and Drug Administration (FDA). Suicidality in children and adolescents being treated with antidepressant medications. <http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm161679.htm> (accessed 2 Aug 2017).
15. Cipriani A, Zhou X, Del Giovane C, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. *Lancet* 2016;388:881-90.
16. Cohen JA, Bukstein O, Walter H, et al. Practice Parameter for the assessment and treatment of children and adolescents with posttraumatic stress disorder. *J Am Acad Child Adolesc Psychiatry* 2010;49:414-30.
17. Gillies D, Taylor F, Gray C, et al. Psychological therapies for the treatment of post-traumatic stress disorder in children and adolescents. *Cochrane Database Syst Rev* 2012;12:CD006726.
18. Gillies D, Maiocchi L, Bhandari AP, et al. Psychological therapies for children and adolescents exposed to trauma. *Cochrane Database Syst Rev* 2016;10:CD012371.
19. Gutermann J, Schreiber F, Matulis S, et al. Psychological treatments for symptoms of posttraumatic stress disorder in children, adolescents, and young adults: a meta-analysis. *Clin Child Fam Psychol Rev* 2016;19:77-93.
20. Lenz AS, Hollenbaugh KM. Meta-analysis of trauma-focused cognitive behavioral therapy for treating PTSD and co-occurring depression among children and adolescents. *Counseling Outcome Research and Evaluation* 2015;6:18-32.
21. National Collaborating Centre for Mental Health (NCCMH). Post-traumatic stress disorder: The management of

- 1
2
3 PTSD in adults and children in primary and secondary care. National Clinical Practice Guideline Number 26.
4
5
6 London: National Institute for Clinical Excellence (NICE), 2005.
7
- 8 22. Cohen J, Mannarino AP, Deblinger E. Treating Trauma and Traumatic Grief in Children and Adolescents. New York:
9
10 Guilford; 2006.
11
- 12 23. Salloum A, Overstreet S. Grief and trauma intervention for children after disaster: exploring coping skills versus
13
14 trauma narration. *Behav Res Ther* 2012;50:169-79.
15
- 16 24. Linden M, Schermuly-Haupt ML. Definition, assessment and rate of psychotherapy side effects. *World Psychiatry*
17
18 2014;13:306-9.
19
- 20 25. Nutt DJ, Sharpe M. Uncritical positive regard? Issues in the efficacy and safety of psychotherapy. *J*
21
22 *Psychopharmacol* 2008;22:3-6.
23
- 24 26. Deblinger E, Mannarino AP, Cohen JA, et al. Trauma-focused cognitive behavioral therapy for children: impact of
25
26 the trauma narrative and treatment length. *Depress Anxiety* 2011;28:67-75.
27
- 28 27. Ahmad A, Larsson B, Sundelin-Wahlsten V. EMDR treatment for children with PTSD: results of a randomized
29
30 controlled trial. *Nord J Psychiatry* 2007;61:349-54.
31
- 32 28. Ruf M, Schauer M, Neuner F, et al. Narrative exposure therapy for 7- to 16-year-olds: A randomized controlled trial
33
34 with traumatized refugee children. *J Trauma Stress* 2010;23:437-45.
35
- 36 29. Mavridis D, Giannatsi M, Cipriani A, et al. A primer on network meta-analysis with emphasis on mental health.
37
38 *Evid Based Ment Health* 2015;18:40-6.
39
- 40 30. Zhang Y, Zhou X, James AC, et al. Comparative efficacy and acceptability of psychotherapies for acute anxiety
41
42 disorders in children and adolescents: study protocol for a network meta-analysis. *BMJ Open* 2015;5:e008572.
43
- 44 31. Zhou X, Hetrick SE, Cuijpers P, et al. Comparative efficacy and acceptability of psychotherapies for depression in
45
46 children and adolescents: a systematic review and network meta-analysis. *World Psychiatry* 2015;14:207-22.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 32. Carrion VG, Weems CF, Ray R, et al. Toward an empirical definition of pediatric PTSD: the phenomenology of
5
6 PTSD in youth. *J Am Acad Child Adolesc Psychiatry* 2002;41:166-73.
7
- 8
9 33. Scheeringa M, Zeanah C, Myers L, et al. Predictive validity in a prospective follow-up of PTSD in preschool
10
11 children. *J Am Acad Child Adolesc Psychiatry* 2005;44:899-906.
12
- 13
14 34. National Collaborating Centre for Mental Health (UK). Post-traumatic stress disorder: The management of PTSD in
15
16 adults and children in primary and secondary care. Gaskell, 2005.
17
- 18
19 35. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders (DSM-III). 3rd edn.
20
21 Washington DC: American Psychiatric Association, 1980.
22
- 23
24 36. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders (DSM-III-R). 3rd
25
26 revised edn. Washington DC: American Psychiatric Association, 1987.
27
- 28
29 37. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders (DSM-IV). 4th edn.
30
31 Washington DC: American Psychiatric Association, 1994.
32
- 33
34 38. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders (DSM-IV-TR). 4th
35
36 edn. Washington DC: American Psychiatric Association, 2000.
37
- 38
39 39. World Health Organization (WHO). The ninth revision of the international classification of diseases and related
40
41 health problems (ICD-9). Geneva: World Health Organization, 1978.
42
- 43
44 40. World Health Organization (WHO). The tenth revision of the international classification of diseases and related
45
46 health problems (ICD-10). Geneva: World Health Organization, 1992.
47
- 48
49 41. Nader KO, Newman E, Weathers FW, et al. Clinician-Administered PTSD scale for children and adolescents for
50
51 DSM-IV (CAPS-CA). Los Angeles, USA: National Center for PTSD & UCLA Trauma Psychiatry Program
52
53 collaboration, 1998.
54
- 55
56 42. Pynoos RS, Rodriguez N, Steinberg A, et al. The UCLA PTSD Reaction Index for DSM-IV (Revision 1). Los
57
58
59
60

- Angeles: UCLA Trauma Psychiatry Program, 1998.
43. Kaufman J, Birmaher B, Brent DA, et al. Schedule for affective disorders and schizophrenia for school-aged children: present and lifetime version (K-SADS-PL): initial reliability and validity data. *J Am Acad Child Adolesc Psychiatry* 1996;36:980-88.
 44. Silverman WK, Albano AM. Anxiety Disorders Interview Schedule for DSM-IV: child and parent versions. San Antonio, TX: Psychological Corporation, 1996.
 45. Franklin CL, Piazza V, Chelminski I, et al. Defining subthreshold PTSD in the DSM-IV literature: a look toward DSM-5. *J Nerv Ment Dis* 2015;203:574-7.
 46. Foa EB, Johnson KM, Feeny NC, et al. The child PTSD symptom scale: a preliminary examination of its psychometric properties. *J Clin Child Psychol* 2001;30:376-84.
 47. Horowitz M, Wilner N, Alvarez W. Impact of event scale: a measure of subjective stress. *Psychosom Med* 1979;41:209-18.
 48. Cuijpers P, Weitz E, Cristea IA, Twisk J. Pre-post effect sizes should be avoided in meta-analyses. *Epidemiol Psychiatr Sci* 2017;26:364-8.
 49. da Costa BR, Nüesch E, Rutjes AW, et al. Combining follow-up and change data is valid in meta-analyses of continuous outcomes: a meta-epidemiological study. *J Clin Epidemiol* 2013;66:847-55.
 50. Cuijpers P, Li J, Hofmann SG, et al. Self-reported versus clinician-rated symptoms of depression as outcome measures in psychotherapy research on depression: a meta-analysis. *Clin Psychol Rev* 2010;30:768-78.
 51. Higgins JPT, Sterne JAC, Savović J, et al. A revised tool for assessing risk of bias in randomized trials In: Chandler J, McKenzie J, Boutron I, Welch V (editors). *Cochrane Methods*. Cochrane Database of Systematic Reviews 2016, Issue 10 (Suppl 1). dx.doi.org/10.1002/14651858.CD201601.
 52. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557-60.

- 1
2
3
4 53. Furukawa TA, Barbui C, Cipriani A, et al. Imputing missing standard deviations in meta-analyses can provide
5
6 accurate results. *J Clin Epidemiol* 2006;59:7-10.
7
8
9 54. Brooks SP, Gelman A. Alternative methods for monitoring convergence of iterative simulations. *J Comput Graph*
10
11 *Stat* 1998;7:434-45.
12
13 55. Chaimani A, Higgins JP, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. *PLoS One*
14
15 2013;8:e76654.
16
17
18 56. Dias S, Welton NJ, Caldwell DM, et al. Checking consistency in mixed treatment comparison meta-analysis. *Stat*
19
20 *Med* 2010;29:932-44.
21
22
23 57. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from
24
25 multiple-treatment meta-analysis: an overview and tutorial. *J Clin Epidemiol* 2011;64:163-71.
26
27
28 58. Salanti G, Del Giovane C, Chaimani A, et al. Evaluating the quality of evidence from a network meta-analysis.
29
30 *PLoS One* 2014;9:e99682.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tables

Table 1 Description of Psychotherapeutic interventions and control condition

Interventions	Abbreviation	Description
<i>Psychotherapeutic Intervention:</i>		
Trauma-focused cognitive-behavioral therapy	TF-CBT	CBT is a combination of cognitive and behavioral techniques. It also involves additional techniques such as relaxation training, affective modulation skills, and enhancement of future safety and development. TF-CBT is a CBT program that involves a trauma focus, which is usually performed through exposure or cognitive processing of thoughts related to the trauma.
Non-trauma-focused cognitive-behavioral therapy	Non-TF-CBT	Non-TF-CBT is a CBT program that focuses on teaching skills for the reduction of anxiety. These treatments utilise procedures that directly target the person's beliefs and behaviors rather than the discussions of specific traumas.
Cognitive therapy	CT	CT mainly uses cognitive restructuring training, which aims at examining youths' automatic thoughts and core schemas and evaluating the accuracy and affective consequences of their views. They aim to teach youths to engage in "rational" thinking about themselves, the traumatic incident, and the world.
Behavioral therapy	BT	BT uses some form of behavioral training, especially for exposure -based therapy and narrative therapy, to help youth reduce trauma-related symptoms. BT is based on principles of habituation.
Eye movement desensitization and reprocessing	EMDR	EMDR aims to help a person reprocess their memories of a traumatic event. The therapy involves bringing distressing trauma-related images, beliefs, and bodily sensations to mind.
Psychodynamic therapy	DYN	Psychodynamic psychotherapy focuses on integrating the traumatic experience into the life experience of the individual as a whole. Childhood issues are often felt to be important.
Play therapy	PT	PT used techniques to engage participants in recreational activities to help them cope with their problems and fears.
Stress management	SM	SM mainly includes some form of relaxation or biofeedback
Supportive therapy	ST	ST is an unstructured therapy without specific psychological techniques that it helped people to ventilate their experiences and emotions and offering empathy. e.g. supportive counseling, attention control, minimal contact, active listening, common factor control, nonspecific control
<i>Control conditions:</i>		
Treatment-as-usual	TAU	TAU is often described as "usual care" or "usual community treatment" in trials, which may include any components of psychotherapy or pharmacotherapy for PTSD. It is not considered to be structured intervention but may have some treatment effects.
Waitlist	WL	WL is a control condition in which the participants receive no active treatment during the study but are informed that they can receive one after the study period is over.
No-treatment	NT	NT is a control condition in which the participants receive no active treatment during the study and in which they do not expect to receive such after the study is over.

Table 2 Hierarchy of PTSD symptom severity measurement scales

Hierarchy	PTSD symptom severity rating scales	Abbreviation
1	UCLA Posttraumatic Stress Disorder Reaction Index	UCLA PTSD Index
2	Child PTSD Symptoms Scale	CPSS
3	Clinician-Administered PTSD Scale/ Clinician Administered PTSD Scale-Child and Adolescent Version	CAPS/ CAPS-CA
4	Impact of Events Scale/ The Children's Revised Impact of Events Scale	IES/ CRIES
5	Parent report of post-traumatic symptoms/Child report of post-traumatic symptoms	PROPS/CROPS
6	Kiddie-Schedule for Affective Disorders and Schizophrenia	K-SADS
7	Trauma Symptom Checklist for Children	TSCC
8	Posttraumatic Cognitions Inventory/Child post-traumatic cognitions inventory	PTCI/CPTCI
9	Harvard Trauma Questionnaire	HTQ
10	Post traumatic Stress Scale	PSS
11	Child Post-Traumatic Stress-Reaction Index	CPTS-RI
12	The Preschool Age Psychiatric Assessment	PAPA
13	Anxiety Disorders Interview Schedule	ADIS

The full search strategy for database

The following explicit search strategy with filters of clinical study will be applied: Condition = [(post-traumatic* or PTSD or PTSS or posttrauma* or trauma* or peritrauma* or peri-trauma* or psychotraumatology or “stress disorder*” or “stress reactions” or “sexually abus*” or “sexual abus*” or “sexually assault*” or “sexual assault*” or “physical abuse*” or “physically abuse*” or “child abuse” or “children abuse” or “natural disaster” or refugee or war or violence or maltreat* or mistreat or acciden* or tsunami* or hurricane* or earthquake or tornado)] AND Intervention = (“trauma focused” or trauma-specific or cogniti* or behavio* or CBT or “eye movement desensitization and reprocessing” or EMDR or EMD or “stress management” or “stress inoculation training” or mindfulness or “art therapy” or “play therapy” or hypnotherapy or biofeedback or counsel* or supportive or interpersonal or bibliotherapy or narrative or narration or exposure* or psychoeducation or “family treatment” or “family therapy” or meditation or relaxation or “problem solving” or “school-based intervention” or “school-based treatment” or “mind-body skills” or “seeking safety” or “mental health” or “writing for recovery” or “psychosocial intervention” or “child centered” or psychodynamic or psychodrama or desensitization or psychological or psychotherap*) AND Age = (adolesc* or boy* or girl* or child* or infant* or juvenil* or minors or pediatri* or paediatric* or pubescen* or puberty or student* or teen* or young or youth* or school* or high-school or preschool* or pre-school* or class*).

The following Medical Subject Headings (MeSH) will also be searched: “Stress Disorders” AND “Psychotherapy” AND (“child” OR “adolescent”).

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Reported on Page #
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	4
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	17
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	
Support:			
Sources	5a	Indicate sources of financial or other support for the review	17
Sponsor	5b	Provide name for the review funder and/or sponsor	17
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	17
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	6-7
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	7-8
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	8-11
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	12
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be	Supplementary

	repeated	material
Study records:		
Data management	11a Describe the mechanism(s) that will be used to manage records and data throughout the review	12
Selection process	11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	12-13
Data collection process	11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	13
Data items	12 List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	13
Outcomes and prioritization	13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	10-11
Risk of bias in individual studies	14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	13
Data synthesis	15a Describe criteria under which study data will be quantitatively synthesised	13-14
	15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	14
	15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	14-15
Meta-bias(es)	16 If quantitative synthesis is not appropriate, describe the type of summary planned	15
Confidence in cumulative evidence	17 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	15

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

BMJ Open

Comparative Efficacy and Acceptability of Psychotherapies for Post-traumatic Stress Disorder in Children and Adolescents: Study Protocol for a Systematic Review and Network Meta-Analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020198.R2
Article Type:	Protocol
Date Submitted by the Author:	25-Jan-2018
Complete List of Authors:	Zhang, Yuqing; The First Affiliated Hospital of Chongqing Medical University, Department of Neurology Zhou, Xinyu; The First Affiliated Hospital of Chongqing Medical University, Department of Psychiatry Yang, Lining; The First Affiliated Hospital of Chongqing Medical University, Department of Neurology Hetrick, Sarah; University of Melbourne, Centre for Youth Mental Health; University of Auckland, Department of Psychological Medicine Weisz, John; Harvard University, Department of Psychology Cuijpers, Pim; VU University Amsterdam, Department of Clinical Psychology Barth, Juergen; University Hospital and University of Zurich, Institute for Complementary and Integrative Medicine Del Giovane, Cinzia; University of Bern, Institute of Primary Health Care (BIHAM) Yuan, Shuai; The First Affiliated Hospital of Chongqing Medical University, Department of Neurology Cohen, David; Institut des Systèmes Intelligents et de Robotiques, UPMC Univ Paris 06, Department of Child and Adolescent Psychiatry Gillies, Donna; Western Sydney Local Health District, Mental Health Jiang, Xiaofeng; The First Affiliated Hospital of Chongqing Medical University, Department of Neurology Teng, Teng; The First Affiliated Hospital of Chongqing Medical University, Department of Neurology Xie, Peng; The First Affiliated Hospital of Chongqing Medical University, Department of Neurology; Chongqing Medical University, Institute of Neuroscience and the Collaborative Innovation Center for Brain Science
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Evidence based practice, Pharmacology and therapeutics, Paediatrics
Keywords:	post-traumatic stress disorder, Child & adolescent psychiatry < PSYCHIATRY, psychotherapy, network meta-analysis, systematic review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SCHOLARONE™
Manuscripts

For peer review only

1
2
3 **Comparative Efficacy and Acceptability of Psychotherapies for Post-traumatic Stress Disorder**
4 **in Children and Adolescents: Study Protocol for a Systematic Review and Network**
5 **Meta-Analysis**
6
7
8
9

10 Yuqing Zhang,¹ Xinyu Zhou,² Lining Yang,¹ Sarah E. Hetrick,³ John R. Weisz,⁴ Pim Cuijpers,⁵ Jürgen Barth,⁶ Cinzia Del
11 Giovane,⁷ Shuai Yuan,¹ David Cohen,⁸ Donna Gillies,⁹ Xiaofeng Jiang,¹ Teng Teng,¹ Peng Xie¹
12
13
14
15

16 ¹ Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute
17 of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing,
18 China
19
20

21 ² Department of Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
22

23 ³ Department of Psychological Medicine, University of Auckland, and the Centre of Youth Mental Health, University of
24 Melbourne, Melbourne, Australia
25
26

27 ⁴ Department of Psychology, Harvard University, Cambridge, MA, USA
28

29 ⁵ Department of Clinical, Neuro and Developmental Psychology, Amsterdam Public Health research institute, Vrije
30 Universiteit Amsterdam, The Netherlands
31

32 ⁶ Institute for Complementary and Integrative Medicine, University Hospital and University of Zurich, Zurich,
33 Switzerland
34
35

36 ⁷ Institute of Primary Health Care (BIHAM), University of Bern, Switzerland
37

38 ⁸ Department of Child and Adolescent Psychiatry, Hôpital Pitié-Salpêtrière, Institut des Systèmes Intelligents et
39 Robotiques, Université Pierre et Marie Curie, Paris, France
40

41 ⁹ Western Sydney Local Health District - Mental Health, Westmead, Australia
42
43
44

45 YZ, XZ and LY contributed equally to this work.
46
47
48

49 **Direct correspondence to:**

50 Prof Peng Xie, Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong
51 District, Chongqing, China; E-mail: xiepeng973@126.com.
52
53
54
55

56 Keywords: post-traumatic stress disorder, child, adolescent, psychotherapy, network meta-analysis, systematic review
57
58
59

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Word count: 3354.

For peer review only

ABSTRACT

Introduction: Post-traumatic stress disorder (PTSD) is common among children and adolescents who are exposed to trauma, and it is often associated with significant negative impacts on their psychosocial functioning and quality of life.

Many types of psychotherapies have been found to be effective for PTSD in children and adolescents. However, due to the lack of direct comparisons between different psychotherapies, the hierarchy of treatment efficacy is still unclear.

Therefore, we plan to conduct a systematic review and network meta-analysis to evaluate the efficacy and acceptability of various types of psychotherapies for PTSD in children and adolescents.

Methods and analysis: A systematic search will be conducted among eight electronic databases, including PubMed, Cochrane, EMBASE, Web of Science, PsycINFO, CINAHL, PILOTS and ProQuest Dissertations, from inception to October 2017. Randomised controlled trials (RCTs), regardless of language, publication year, and publication type, comparing any psychotherapies for PTSD to any control condition or alternative treatment in children and adolescents (18 years old or less) diagnosed with full or subclinical PTSD will be included. Study duration and the number of treatment sessions will not be limited. The primary outcome will be PTSD symptom severity at post-treatment as measured by a rating scale reported by the child, parent, or a clinician. The secondary outcomes will include (1) efficacy at follow-up; (2) acceptability (all-cause discontinuation); (3) anxiety symptom severity; (4) depressive symptom severity; and (5) quality of life and functional improvement. Bayesian network meta-analyses for all relative outcome measures will be performed. We will conduct subgroup and sensitivity network meta-analyses to determine whether the findings are affected by study characteristics. The quality of the evidence contributing to network estimates of the primary outcome will be evaluated by the GRADE framework.

Ethics and dissemination: No ethical issues are foreseen. The results will be published in a peer-reviewed journal, which will be disseminated electronically and in print. This network meta-analysis may be updated to inform and guide the clinical management of PTSD in children and adolescents.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Trial registration number: PROSPERO CRD42016051786.

For peer review only

Strengths and limitations of this study

1. Bayesian network meta-analysis can simultaneously compare various types of treatments by integrating all the best evidence (direct and indirect evidence) to estimate the interrelations across all treatments and establish a treatment hierarchy for psychotherapies for post-traumatic stress disorder in children and adolescents.
2. A number of outcomes will be used to comprehensively assess efficacy at post-treatment and follow-up, acceptability, anxiety and depressive symptom severity, quality of life and functional improvement.
3. This study will help to guide clinical decision-making regarding the relative efficacy of various types of psychotherapy, and various delivery modalities, in the treatment of post-traumatic stress disorder in children and adolescents.
4. Subgroup and sensitivity network meta-analyses will help to find potential moderators that affect the efficacy of psychotherapies.
5. The limitations of included studies will be assessed using the Cochrane Collaboration's Risk of bias' 2.0 tool and the quality of evidence for network estimates of the primary outcome will be evaluated by the GRADE framework.

BACKGROUND

Many children and adolescents are exposed to trauma, with more than two thirds reporting at least 1 traumatic event by 16 years of age.¹ Post-traumatic stress disorder (PTSD) is one of the most common mental disorders among children and adolescents who have experienced trauma. Data from a meta-analysis pooling 72 articles with 3563 trauma-exposed children and adolescents show that the overall rate of PTSD was 15.9%.² As described in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), PTSD diagnostic criteria includes four symptom clusters: (1) re-experiencing of the traumatic event, (2) avoidance of stimuli associated with the traumatic event, (3) negative alterations in cognition and mood, (4) hyperarousal.³ Trauma exposure is an essential factor in order to be able to diagnose PTSD, which can include physical or sexual abuse, war or terrorism, natural or man-made disasters, witnessing domestic violence, catastrophic illnesses, vehicle or other accidents.^{4,5} PTSD is correlated with various adverse consequences for children and adolescents in cognitive, emotional, social, academic, and other functional domains.⁶ In addition, PTSD commonly co-occurs with other psychiatric conditions, such as major depressive disorder,⁷ anxiety disorder,⁷ substance abuse,⁸ and attention deficit hyperactivity disorder (ADHD).⁹ PTSD diagnosis is accompanied by a significant reduction in quality of life, and it is estimated that successful treatment could save 2.05 quality adjusted life years (QALYs) per child or adolescent with PTSD.¹⁰

Several forms of interventions have been applied to address PTSD symptoms in children and adolescents, from which psychotherapy is the mainstay of treatment.¹¹ Although some medications (e.g., fluoxetine, paroxetine and venlafaxine) have shown a significant but small superiority over placebo (mean effect size=0.23) in PTSD treatment for adults,¹² their use in children and adolescents is still limited because (1) the evidence of the effectiveness of pharmacological treatments for children and adolescents with PTSD is scant;¹³ and, (2) medications have been associated with safety concerns in children and adolescents, including evidence of increased risk of suicidality in children and adolescents treated with antidepressants.^{14,15} Therefore, clinical guidelines recommend that psychotherapy should be used

1
2
3 for the initial treatment of PTSD in children and adolescents.¹⁶
4
5

6 Since the 1990s, psychotherapies have been increasingly applied in the treatment of PTSD in children and
7 adolescents, and recent reviews have reported encouraging results on their efficacy.¹⁷⁻¹⁹ Evidence from Cochrane reviews
8 found that psychological therapies are not only effective in preventing PTSD in children and adolescents who have
9 undergone trauma, but also effective in treating PTSD in children and adolescents.^{17,18} Many types of psychotherapies are
10 now available, such as cognitive behavioral therapy (CBT), eye movement desensitization and reprocessing (EMDR),
11 behavioral therapy (BT), cognitive therapy, psychodynamic therapy and play therapy. Among these, trauma-focused CBT
12 (TF-CBT), a CBT program that uses cognitive-behavioral techniques with a trauma-focused component, is the most
13 commonly practiced psychotherapy for children and adolescents with PTSD.²⁰ TF-CBT has been recommended as a
14 first-line treatment by clinical guidelines for PTSD in children and adolescents.^{16,21} However, trauma-focused therapy can
15 be difficult for some therapists to implement,^{22,23} and there are some safety concerns in clinical practice (e.g. symptoms
16 worsening and patients ending treatment prematurely).^{24,25} Two recent trials that directly compared TF-CBT with
17 non-TF-CBT alternatives reported that both were efficacious.^{23,26} Thus, whether the inclusion of a trauma-focused
18 component is essential in CBT for PTSD in children and adolescents is still uncertain. Moreover, other therapies, such as
19 EMDR and BT, have also been reported effective in treating PTSD symptoms in children and adolescents.^{27,28} However,
20 due to methodological limitations, conventional meta-analyses cannot simultaneously compare all these treatments.
21 Therefore, they cannot provide a clear answer regarding the best choice for initial treatment, nor can they provide a
22 hierarchy of these psychotherapies.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 Network meta-analysis is a newly developed method for evidence synthesis, which is able to integrate direct
47 evidence (from studies directly comparing interventions) with indirect evidence (derived from separate studies
48 addressing a common reference condition) from multiple treatment comparisons to estimate the interrelations across all
49 treatments.²⁹ This approach enables a simultaneous comparison of multiple treatments, and can provide hierarchical
50
51
52
53
54
55
56

1
2
3 evidence to guide clinical practice. Using this method, our group has produced meta-analyses comparing the effects of
4
5 different psychotherapies for the treatment of anxiety disorder³⁰ and depressive disorder³¹ in children and adolescents. In
6
7 the present study we describe the methods to undertake a network meta-analysis to complement those previous reports
8
9 that will focus on the efficacy of psychotherapies for children and adolescents with PTSD. By performing a
10
11 well-designed Bayesian network meta-analysis, we aim to provide a higher level of evidence that can inform clinical
12
13 guidelines for PTSD treatment in children and adolescents.
14
15
16
17
18

19 **METHODS**

20 **Criteria for included studies**

21 *Types of studies*

22
23 All randomised controlled trials (RCTs), including cluster-randomised trials and cross-over trials, will be included.
24
25 However, only the results from the first randomisation period will be considered in the cross-over trials. For the purpose
26
27 of reducing heterogeneity between trials, we will exclude quasi-randomised trials (e.g., allocation based on the last
28
29 number of the date of birth) and trials in which the sample size is less than 10 per study. Study duration and the number
30
31 of treatment sessions will not be limited.
32
33
34
35
36
37
38

39 *Types of participants*

40
41 Studies that enrolled children and adolescents, aged 18 years old or less when they were initially enrolled, will be
42
43 included in this review. Given that children with significant PTSD symptoms who do not meet full criteria for a PTSD
44
45 diagnosis often have comparable functional impairment to those with a PTSD diagnosis,³²⁻³⁴ the clinical guideline
46
47 suggested that treatment decisions should be based on symptom severity and functional impairment, rather than whether
48
49 or not they have an actual PTSD diagnosis.¹⁶ Therefore, we will apply the following broad criteria to identify the
50
51 participants: (1) Full PTSD, as diagnosed according to standardised diagnostic interviews based on international
52
53 classifications (the Diagnostic and Statistical Manual of Mental Disorders (DSM),^{3,35-38} the International Classification of
54
55
56
57
58
59
60

1
2
3 Diseases (ICD)^{39,40} or validated scales for PTSD based on DSM/ ICD criteria;⁴¹⁻⁴⁴ (2) Subclinical/Partial PTSD, defined
4 as patients who have experienced psychological trauma and report some subsequent PTSD symptoms in at least one of
5
6 the four symptom clusters according to DSM-5 (i.e., reexperiencing, avoidance, hyperarousal, negative alterations in
7
8 cognition and mood);⁴⁵ (3) Clinically significant posttraumatic stress symptoms, defined as scoring above a validated
9
10 cutoff on a PTSD rating scale, such as the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS)⁴², Child
11
12 PTSD Symptoms Scale (CPSS)⁴⁶ and the Impact of Event Scale (IES)⁴⁷. We will include trials in which participants have
13
14 a secondary diagnosis of comorbid general psychiatric disorders, e.g., depressive disorder, anxiety disorder, attention
15
16 deficit hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD). However, trials in which participants
17
18 have a diagnosis of acute stress disorder (ASD) or adjustment disorder (AD) will be excluded. Studies where both adults
19
20 and children/adolescents are included will be eligible for inclusion, if the data for the latter can be obtained separately.
21
22
23 Studies where it is not clear what happened to the patients who withdrew from the study will not be excluded, and all
24
25 these patients will be counted as all-cause discontinuation. Trials conducted in any treatment settings, including
26
27 outpatient clinics, inpatient services, community clinics and schools will be included.

28 ***Types of interventions***

29
30 All RCTs comparing any psychotherapy against another psychotherapy or any control condition for children and
31
32 adolescents with PTSD will be included. We will view each of: trauma-focused CBT (TF-CBT), non-trauma-focused
33
34 CBT (Non-TF-CBT), eye movement desensitization and reprocessing (EMDR), behavioral therapy (BT), cognitive
35
36 therapy (CT), psychodynamic therapy (DYN), play therapy (PT), and any other psychotherapy as independent nodes in
37
38 this network meta-analysis. Trials comparing the same type of psychotherapies, but at different delivery conditions (with
39
40 or without family involvement), different delivery formats (group, individual, or group plus individual) and different
41
42 delivery mediums (face-to-face, internet-based) will be considered as the same node in this network meta-analysis.
43
44
45 Nevertheless, because TF-CBT is the most commonly studied psychotherapy and recommended by clinical guidelines as
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 first-line choice for children and adolescents with PTSD,^{16,21} if data available, we will separate TF-CBT with different
4
5
6 delivery conditions, formats, and mediums as independent nodes.
7

8 Control conditions can include waitlist (WL), non-treatment (NT), and treatment as usual (TAU). We will view each
9
10 of these control conditions as independent nodes in this network meta-analysis. The detailed description of each
11
12 treatment and control condition are presented in Table 1. According to the principles described in this table, two
13
14 reviewers will independently perform the classification of all conditions in each trial. Any disagreements will be
15
16 discussed among the review team, and any unclear information will be requested from the relevant authors.
17
18
19

20 Studies where psychotherapy is used as a combination strategy (e.g., combining psychotherapy with medication)
21
22 will be excluded, because such designs make it impossible for us to estimate the effect size of each specific treatment
23
24 approach. We will not exclude studies that enrolled patients who had used medications in the past, provided that their
25
26 medication status was not changed for at least one month prior to study entry and for the study period.
27
28
29

30 *Types of outcome measures*

31 *Primary outcome*

32
33
34 1. Efficacy at post-treatment, as measured using the end point score from PTSD symptom severity rating scales
35
36 completed by the child, parent, or a clinician.⁴⁸ When end point scores are not reported, we will use change scores (if
37
38 available).⁴⁹ Where more than one scale is reported in a trial, we will extract data from the PTSD symptom scales on a
39
40 hierarchy, which is based on psychometric properties and appropriateness for use with children and adolescents (Table 2).
41
42 In addition, where a PTSD symptom scale is reported by different raters in a trial, self-rated outcome will be preferred,
43
44 then the parent or clinician rated outcome, because self-rated outcome tends to result in more conservative effect sizes.⁵⁰
45
46
47 Where dichotomous efficacy outcomes, instead of continuous scores, are reported in a trial, we will contact the relevant
48
49 authors to request the data we need. If they didn't respond the data will not be used.
50
51
52

53 *Secondary outcomes*

54
55
56 1. Efficacy at follow-up, as measured by the score from PTSD scales at the longest point of follow-up (up to 12
57
58
59
60

1
2
3 months). The selection priority of PTSD scales will be the same as for efficacy at post-treatment. Data from participants
4
5 who take part in subsequent treatments (e.g., continuing psychotherapy/pharmacotherapy or booster sessions) will be
6
7 excluded in the follow-up analysis.
8
9

10
11 2. Acceptability, defined as all-cause discontinuation, as measured by the proportion of patients who discontinued
12
13 treatment for any cause at the end of treatment. Notably, children and adolescents may discontinue treatment for many
14
15 different reasons, such as finding it difficult to adhere to long-term treatment, because symptoms worsen, or due to rapid
16
17 improvement of symptoms.³⁰
18
19

20
21 3. Anxiety symptoms, as measured by the end point score on anxiety symptom severity rating scales. The following
22
23 scales will be used: Revised Children's Manifest Anxiety Scale (RCMAS), Spence Children's Anxiety Scale (SCAS),
24
25 Multidimensional Anxiety Scale for Children (MASC), State-Trait Anxiety Inventory for Children (STAIC), Screen for
26
27 Anxiety and Related Disorders (SCARED). If none of above scales are reported, other valid anxiety scales will be used.
28
29 When a scale is reported by different raters in a trial, self-rated outcome will be preferred.
30
31
32

33
34 4. Depressive symptoms, as measured by the end point score on depressive symptom severity rating scales. The
35
36 following scales will used: Children's Depression Inventory (CDI), Beck depression inventory (BDI), Mood and Feeling
37
38 Questionnaire (MFQ), Children's Depression Rating Scale Revised (CDRS-R), Hamilton Depression Rating Scale
39
40 (HAMD). As for anxiety, other valid depression scales will be used if none of the above scales were reported.
41
42

43
44 5. Quality of life and functional improvement (QoL/functioning). If data are available, we will extract continuous
45
46 outcomes from scales of quality of life and functional improvement measured at post-treatment. The scales of quality of
47
48 life include Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), Pediatric Quality of Life Inventory
49
50 (QoL Child Report), the Quality of Life Inventory (QoLI), and others. The scales of functional improvement include the
51
52 Children's Global Assessment Scale (CGAS), the Global Assessment Functioning (GAF), and others. When scales of
53
54 quality of life and functional improvement are both reported in a trial, we will extract the data of quality of life.
55
56
57

Search strategy

We will identify relevant trials from systematic searches in the following electronic databases: PubMed, Cochrane, EMBASE, Web of Science, PsycINFO, CINAHL, PILOTS and ProQuest Dissertations. The timeline will be from database inception to October 2017. An example of search strategy for PubMed is included in the supplementary material. In addition, international trials registers, such as World Health Organization's trials portal, ClinicalTrials.gov and Australian New Zealand Clinical Trials Registry (ANZCTR) will be searched for ongoing trials. Furthermore, we will search the presentations at European Psychiatric Association (EPA), European College of Neuropsychopharmacology (ECNP), American Psychological Association (APA), American Psychiatric Association (APA) and European Society for Child and Adolescent Psychiatry (ESCAP) congresses and hand-search relevant key psychiatric, psychological and medical journals (including *Behavior Therapy*, *Child Abuse and Neglect*, *Child Maltreatment*, *Journal of Counseling and Development*, *Counseling Outcome Research and Evaluation*, *Journal of Anxiety Disorders*, *Journal of Mental Health Counseling*, *Journal of Trauma Practice*, *Journal of Traumatic Stress*, *Journal of the American Academy of Child and Adolescent Psychiatry*, *Journal of Consulting and Clinical Psychology*, *Behaviour research and therapy*). The reference lists of included trials and reviews identified from initial searches will be scanned for more relevant studies. All relevant authors will be contacted to complement the incomplete data.

Study selection and data extraction

Selection of trials

Two reviewers (YZ and LY) will independently identify potentially eligible studies from the titles and abstracts of records from the search strategies. Studies will be excluded if both reviewers consider that it does not meet eligibility criteria. Then, the full texts of these potentially eligible studies will be reviewed by the same criteria. The inter-rater reliability of the two reviewers will be calculated to detect their consistency. All disagreements will be discussed and resolved by a senior review author (PX or SEH). The references of relevant reviews and included trials will be checked

1
2
3 by YZ and LY. Where multiple publications derive from a common data set, we will select the trials in which the relevant
4
5 outcomes we predefined in this protocol were reported completely. We will report the reasons for exclusion for each trial
6
7 in the characteristics of excluded studies list. Finally, a flow chart will be used to present the process of trial screening in
8
9 this meta-analysis.
10
11

12 ***Risk of bias assessment***

13
14
15 Two reviewers (YZ and XZ) will independently assess the methodological quality of the included studies.
16
17 According to the Cochrane Collaboration's Risk of bias' 2.0 tool,⁵¹ the risk of bias will be rated as "low risk", "high risk",
18
19 or "some concerns" in the following domains: (1) bias arising from the randomization process, (2) bias due to deviations
20
21 from intended interventions, (3) bias due to missing outcome data, (4) bias in measurement of the outcome, (5) bias in
22
23 selection of the reported result, (6) overall bias. The inter-rater reliability of the two reviewers assessing the risk of bias
24
25 will also be calculated. Any disagreements will be resolved by a senior review author (PX or SEH).
26
27
28
29

30 ***Data extraction***

31
32
33 A standardised data extraction form will be used by two independent reviewers (YZ and XZ) to record the relevant
34
35 parameters from the original paper, including study characteristics (e.g., title, first author, publication year, publication
36
37 type, publication journal, location, and sponsor), patient characteristics (e.g., diagnostic criteria for PTSD, type of trauma,
38
39 severity of PTSD symptoms, comorbidities, and the number, mean age and gender of participants), intervention details
40
41 (e.g., type of psychotherapy, treatment format, treatment setting, treatment duration, the number of sessions, follow-up
42
43 duration, and co-interventions) and outcome measures (mean scores, number of participants, and outcome raters (i.e., self
44
45 rated or observer rated) for each pre-defined outcome). A table will be used to present the main characteristics of each
46
47 study included in this review. The reliability of data extraction from the reviewers will also be assessed. Any
48
49 disagreements will be resolved by a senior review author (PX or SEH).
50
51
52
53

54 ***Statistical analysis***

1
2
3 We will perform Bayesian network meta-analysis for each outcome with random-effects model in WinBUGS
4
5 (version 1.4.3). In addition, as a reference for relative outcomes of network meta-analyses, conventional pairwise
6
7 meta-analyses will also be performed for each outcome with a random-effects model in Stata (version 13.0). Standardised
8
9 mean difference (SMD, Cohen's d) will be used as a measure of effect size where outcome is measured on different
10
11 scales. For dichotomous outcome (all-cause discontinuation), the effect sizes will be calculated as odds ratios (OR).
12
13 Statistical heterogeneity in each pairwise comparison will be assessed with the I^2 statistic and p value.⁵² When the mean
14
15 values or SDs of continuous outcomes are missing, we will compute values by conversion from p-values, t-values,
16
17 confidence intervals or standard errors.⁵³ Missing continuous outcome data will be analysed using completer data.
18
19
20
21
22

23 The pooled estimates of network meta-analysis will be obtained using the Markov Chains Monte Carlo method. Two
24
25 Markov chains will be run simultaneously with different arbitrarily chosen initial values. Trace plots and the
26
27 Brooks-Gelman-Rubin statistic will be monitored to ensure convergence.⁵⁴ When the model is adequately convergent, the
28
29 foregoing samples will be discarded. Then 100,000 subsequent simulations will be run as the posterior summaries. All
30
31 results will be reported as effect sizes (SMD or OR) and their 95% credible intervals (CrI). We will assume a common
32
33 heterogeneity parameter for each comparison and assess the global heterogeneity using the I^2 statistic with 'gemtc'
34
35 package in R (version 3.2.2). Furthermore, the inconsistency between direct and indirect evidence will be evaluated,
36
37 which will include the assessment of global inconsistency (by comparing the fit and parsimony of consistency and
38
39 inconsistency models), local inconsistency (by calculating the difference among direct and indirect evidence in closed
40
41 loops in the network)⁵⁵ and the inconsistency calculated by node splitting method (by assessing the difference between
42
43 direct and indirect estimates within a particular comparison).⁵⁶ Probability values will be summarised and reported as
44
45 surface under the cumulative ranking curve (SUCRA) to provide a hierarchy of the treatments.⁵⁷
46
47
48
49
50
51

52 ***Subgroup analysis***

53
54 Where possible, we will conduct network meta-regression of data on primary outcome, to evaluate the influence of
55
56

1
2
3 the following potential moderators: (1) age group; (2) sex ratio; (3) number of sessions; (4) sample size; (5) risk of bias;
4
5
6 (6) trauma types (acute/single trauma vs chronic trauma); (7) diagnosis criteria (youth with a diagnosis vs with
7
8 subsyndromal symptoms); (8) source of outcome measure (self-rated vs observer-rated). If the data are insufficient to
9
10 conduct subgroup analyses for some moderators, we will perform sensitivity analyses by omitting specific trials from the
11
12 overall analysis.
13
14

15 ***Other analyses***

16
17
18 Comparison-adjusted funnel plots and Egger's test will be used for each outcome to examine whether there is
19
20 dominant publication bias exist in this network meta-analysis.⁵⁶ In addition, we will evaluate the quality of evidence for
21
22 primary outcome by using the GRADE framework, which characterises the quality of a body of evidence on the basis of
23
24 the study limitations, imprecision, inconsistency, indirectness, and publication bias for network estimates.⁵⁸
25
26
27

28 **Discussion**

29
30 This systematic review and network meta-analysis will comprehensively evaluate the comparative efficacy and
31
32 acceptability of psychological interventions for children and adolescents with PTSD. The results of this research will
33
34 provide evidence to inform a hierarchy of comparative efficacy at post-treatment, efficacy with regard to PTSD
35
36 symptoms at follow-up, as well as in terms of acceptability (all-cause discontinuation), improvement of anxiety
37
38 symptoms, improvement of depressive symptoms, and quality of life and functional improvement. We expect that the
39
40 findings could assist patients, clinicians and healthcare providers to make a better-informed choice in treatment selection.
41
42
43
44

45 There are some limitations in this protocol. First, due to the fact that PTSD commonly co-occurs with other
46
47 psychiatric comorbidities, we will not exclude trials in which patients with comorbidity were enrolled. This will enhance
48
49 the generalizability of this study; however, it will also raise the risk of bias for outcomes. Further individual patient data
50
51 meta-analysis will be helpful to investigate the influence of this factor. Second, some trials may tend to report their
52
53 favourite outcomes. Although we have predefined the data selection criteria for each outcome, this selection bias could
54
55
56
57

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

not be completely eliminated.

Ethics and dissemination

This network meta-analysis will use data in the public domain. Therefore, no formal ethical assessment and informed consent are required. The results will be published in a peer-reviewed journal and disseminated electronically and in print.

For peer review only

Contributors

PX, YZ and XZ conceived the study and drafted the manuscript. SEH, JRW, PC, JB, CDG, DC, DG assisted in protocol design and revision. YZ, XZ, LY, SY, XJ, and TT participated in the search strategy development, and will carry out the most work of study selection, risk of bias assessment, and data collection. PX, and SEH will help to resolve the disagreements and check the data. CDG, YZ and XZ participated in the design of data synthesis and analysis, and will conduct the statistical analyses. All the authors have approved the publication of the protocol.

Funding This work is supported by National Key Research and Development Programm of China (Grant No.2017YFA0505700). The funders had no role in the protocol design; the writing of the protocol; or the decision to submit the protocol for publication.

Competing interests SEH is an editor of the Cochrane Common Mental Disorders Group, and an author on the Cochrane systematic review on treatments for PTSD in young people. During the last two years, David Cohen reported past consultation for or the receipt of honoraria from Otsuka, Shire, Lundbeck and Roche. DG is the primary author of two reviews of psychological therapies for children and adolescents who were diagnosed with PTSD or exposed to trauma. YZ, XZ, LY, JRW, PC, JB, CDG, SY, XJ, TT, and PX declare no competing interests.

Provenance and peer review Not commissioned; externally peer-reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution- Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

- 1 Copeland WE, Keeler G, Angold A, et al. Traumatic events and post-traumatic stress in childhood. *Arch General Psychiatry* 2007;64:577-84.
- 2 Alisic E, Zalta AK, Van Wesel F, et al. Rates of post-traumatic stress disorder in trauma-exposed children and adolescents: meta-analysis. *Br J Psychiatry* 2014;204:335-40.
- 3 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edn. Arlington, VA: American Psychiatric Publishing, 2013.
- 4 Donnelly CL, Amaya-Jackson L. Post-traumatic stress disorder in children and adolescents: epidemiology, diagnosis and treatment options. *Paediatr Drugs* 2002;4:159-70.
- 5 Taylor TL, Chemtob CM. Efficacy of treatment for child and adolescent traumatic stress. *Arch Pediatr Adolesc Med* 2004;158:786-91.
- 6 Dorsey S, McLaughlin KA, Kerns SEU, et al. Evidence Base Update for Psychosocial Treatments for Children and Adolescents Exposed to Traumatic Events. *J Clin Child Adolesc Psychol* 2017;46:303-30.
- 7 Dixon A, Howie P, Starling J. Trauma exposure, posttraumatic stress, and psychiatric comorbidity in female juvenile offenders. *J Am Acad Child Adolesc Psychiatry* 2005;44:798-806.
- 8 Lipschiz D, Rasmussen AM, Anyan W, et al. Posttraumatic stress disorder and substance use in inner city girls. *J Nervous Mental Disease* 2003;191:714-21.
- 9 Ford JD, Racusin R, Ellis CG, et al. Child maltreatment, other trauma exposure and posttraumatic symptomatology among children with oppositional disorder and attention deficit hyperactivity disorders. *Child Maltreat* 2000;5:205-17.
- 10 Gospodarevskaya E. Post-traumatic stress disorder and quality of life in sexually abused Australian children. *J Child Sex Abus* 2013;22:277-96.
- 11 Keeshin BR, Strawn JR. Psychological and pharmacologic treatment of youth with posttraumatic stress disorder: an

- evidence-based review. *Child Adolesc Psychiatr Clin N Am* 2014;23:399-411,
12. Hoskins M, Pearce J, Bethell A, et al. Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. *Br J Psychiatry* 2015;206:93-100.
 13. Bajor LA, Ticlea AN, Osser DN. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on posttraumatic stress disorder. *Harv Rev Psychiatry* 2011;19:240-58.
 14. U.S. Food and Drug Administration (FDA). Suicidality in children and adolescents being treated with antidepressant medications. <http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm161679.htm> (accessed 2 Aug 2017).
 15. Cipriani A, Zhou X, Del Giovane C, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. *Lancet* 2016;388:881-90.
 16. Cohen JA, Bukstein O, Walter H, et al. Practice Parameter for the assessment and treatment of children and adolescents with posttraumatic stress disorder. *J Am Acad Child Adolesc Psychiatry* 2010;49:414-30.
 17. Gillies D, Taylor F, Gray C, et al. Psychological therapies for the treatment of post-traumatic stress disorder in children and adolescents. *Cochrane Database Syst Rev* 2012;12:CD006726.
 18. Gillies D, Maiocchi L, Bhandari AP, et al. Psychological therapies for children and adolescents exposed to trauma. *Cochrane Database Syst Rev* 2016;10:CD012371.
 19. Gutermann J, Schreiber F, Matulis S, et al. Psychological treatments for symptoms of posttraumatic stress disorder in children, adolescents, and young adults: a meta-analysis. *Clin Child Fam Psychol Rev* 2016;19:77-93.
 20. Lenz AS, Hollenbaugh KM. Meta-analysis of trauma-focused cognitive behavioral therapy for treating PTSD and co-occurring depression among children and adolescents. *Counseling Outcome Research and Evaluation* 2015;6:18-32.
 21. National Collaborating Centre for Mental Health (NCCMH). Post-traumatic stress disorder: The management of

- 1
2
3 PTSD in adults and children in primary and secondary care. National Clinical Practice Guideline Number 26.
4
5
6 London: National Institute for Clinical Excellence (NICE), 2005.
7
- 8 22. Cohen J, Mannarino AP, Deblinger E. Treating Trauma and Traumatic Grief in Children and Adolescents. New York:
9
10 Guilford; 2006.
11
- 12 23. Salloum A, Overstreet S. Grief and trauma intervention for children after disaster: exploring coping skills versus
13
14 trauma narration. *Behav Res Ther* 2012;50:169-79.
15
- 16 24. Linden M, Schermuly-Haupt ML. Definition, assessment and rate of psychotherapy side effects. *World Psychiatry*
17
18 2014;13:306-9.
19
- 20 25. Nutt DJ, Sharpe M. Uncritical positive regard? Issues in the efficacy and safety of psychotherapy. *J*
21
22 *Psychopharmacol* 2008;22:3-6.
23
- 24 26. Deblinger E, Mannarino AP, Cohen JA, et al. Trauma-focused cognitive behavioral therapy for children: impact of
25
26 the trauma narrative and treatment length. *Depress Anxiety* 2011;28:67-75.
27
- 28 27. Ahmad A, Larsson B, Sundelin-Wahlsten V. EMDR treatment for children with PTSD: results of a randomized
29
30 controlled trial. *Nord J Psychiatry* 2007;61:349-54.
31
- 32 28. Ruf M, Schauer M, Neuner F, et al. Narrative exposure therapy for 7- to 16-year-olds: A randomized controlled trial
33
34 with traumatized refugee children. *J Trauma Stress* 2010;23:437-45.
35
- 36 29. Mavridis D, Giannatsi M, Cipriani A, et al. A primer on network meta-analysis with emphasis on mental health.
37
38 *Evid Based Ment Health* 2015;18:40-6.
39
- 40 30. Zhang Y, Zhou X, James AC, et al. Comparative efficacy and acceptability of psychotherapies for acute anxiety
41
42 disorders in children and adolescents: study protocol for a network meta-analysis. *BMJ Open* 2015;5:e008572.
43
- 44 31. Zhou X, Hetrick SE, Cuijpers P, et al. Comparative efficacy and acceptability of psychotherapies for depression in
45
46 children and adolescents: a systematic review and network meta-analysis. *World Psychiatry* 2015;14:207-22.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 32. Carrion VG, Weems CF, Ray R, et al. Toward an empirical definition of pediatric PTSD: the phenomenology of
5
6 PTSD in youth. *J Am Acad Child Adolesc Psychiatry* 2002;41:166-73.
7
- 8
9 33. Scheeringa M, Zeanah C, Myers L, et al. Predictive validity in a prospective follow-up of PTSD in preschool
10
11 children. *J Am Acad Child Adolesc Psychiatry* 2005;44:899-906.
12
- 13
14 34. National Collaborating Centre for Mental Health (UK). Post-traumatic stress disorder: The management of PTSD in
15
16 adults and children in primary and secondary care. Gaskell, 2005.
17
- 18
19 35. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders (DSM-III). 3rd edn.
20
21 Washington DC: American Psychiatric Association, 1980.
22
- 23
24 36. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders (DSM-III-R). 3rd
25
26 revised edn. Washington DC: American Psychiatric Association, 1987.
27
- 28
29 37. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders (DSM-IV). 4th edn.
30
31 Washington DC: American Psychiatric Association, 1994.
32
- 33
34 38. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders (DSM-IV-TR). 4th
35
36 edn. Washington DC: American Psychiatric Association, 2000.
37
- 38
39 39. World Health Organization (WHO). The ninth revision of the international classification of diseases and related
40
41 health problems (ICD-9). Geneva: World Health Organization, 1978.
42
- 43
44 40. World Health Organization (WHO). The tenth revision of the international classification of diseases and related
45
46 health problems (ICD-10). Geneva: World Health Organization, 1992.
47
- 48
49 41. Nader KO, Newman E, Weathers FW, et al. Clinician-Administered PTSD scale for children and adolescents for
50
51 DSM-IV (CAPS-CA). Los Angeles, USA: National Center for PTSD & UCLA Trauma Psychiatry Program
52
53 collaboration, 1998.
54
- 55
56 42. Pynoos RS, Rodriguez N, Steinberg A, et al. The UCLA PTSD Reaction Index for DSM-IV (Revision 1). Los
57
58
59
60

- Angeles: UCLA Trauma Psychiatry Program, 1998.
43. Kaufman J, Birmaher B, Brent DA, et al. Schedule for affective disorders and schizophrenia for school-aged children: present and lifetime version (K-SADS-PL): initial reliability and validity data. *J Am Acad Child Adolesc Psychiatry* 1996;36:980-88.
 44. Silverman WK, Albano AM. Anxiety Disorders Interview Schedule for DSM-IV: child and parent versions. San Antonio, TX: Psychological Corporation, 1996.
 45. Franklin CL, Piazza V, Chelminski I, et al. Defining subthreshold PTSD in the DSM-IV literature: a look toward DSM-5. *J Nerv Ment Dis* 2015;203:574-7.
 46. Foa EB, Johnson KM, Feeny NC, et al. The child PTSD symptom scale: a preliminary examination of its psychometric properties. *J Clin Child Psychol* 2001;30:376-84.
 47. Horowitz M, Wilner N, Alvarez W. Impact of event scale: a measure of subjective stress. *Psychosom Med* 1979;41:209-18.
 48. Cuijpers P, Weitz E, Cristea IA, Twisk J. Pre-post effect sizes should be avoided in meta-analyses. *Epidemiol Psychiatr Sci* 2017;26:364-8.
 49. da Costa BR, Nüesch E, Rutjes AW, et al. Combining follow-up and change data is valid in meta-analyses of continuous outcomes: a meta-epidemiological study. *J Clin Epidemiol* 2013;66:847-55.
 50. Cuijpers P, Li J, Hofmann SG, et al. Self-reported versus clinician-rated symptoms of depression as outcome measures in psychotherapy research on depression: a meta-analysis. *Clin Psychol Rev* 2010;30:768-78.
 51. Higgins JPT, Sterne JAC, Savović J, et al. A revised tool for assessing risk of bias in randomized trials In: Chandler J, McKenzie J, Boutron I, Welch V (editors). *Cochrane Methods*. Cochrane Database of Systematic Reviews 2016, Issue 10 (Suppl 1). dx.doi.org/10.1002/14651858.CD201601.
 52. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557-60.

- 1
2
3
4 53. Furukawa TA, Barbui C, Cipriani A, et al. Imputing missing standard deviations in meta-analyses can provide
5
6 accurate results. *J Clin Epidemiol* 2006;59:7-10.
7
8
9 54. Brooks SP, Gelman A. Alternative methods for monitoring convergence of iterative simulations. *J Comput Graph*
10
11 *Stat* 1998;7:434-45.
12
13 55. Chaimani A, Higgins JP, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. *PLoS One*
14
15 2013;8:e76654.
16
17
18 56. Dias S, Welton NJ, Caldwell DM, et al. Checking consistency in mixed treatment comparison meta-analysis. *Stat*
19
20 *Med* 2010;29:932-44.
21
22
23 57. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from
24
25 multiple-treatment meta-analysis: an overview and tutorial. *J Clin Epidemiol* 2011;64:163-71.
26
27
28 58. Salanti G, Del Giovane C, Chaimani A, et al. Evaluating the quality of evidence from a network meta-analysis.
29
30 *PLoS One* 2014;9:e99682.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tables

Table 1 Description of Psychotherapeutic interventions and control condition

Interventions	Abbreviation	Description
<i>Psychotherapeutic Intervention:</i>		
Trauma-focused cognitive-behavioral therapy	TF-CBT	CBT is a combination of cognitive and behavioral techniques. It also involves additional techniques such as relaxation training, affective modulation skills, and enhancement of future safety and development. TF-CBT is a CBT program that involves a trauma focus, which is usually performed through exposure or cognitive processing of thoughts related to the trauma.
Non-trauma-focused cognitive-behavioral therapy	Non-TF-CBT	Non-TF-CBT is a CBT program that focuses on teaching skills for the reduction of anxiety. These treatments utilise procedures that directly target the person's beliefs and behaviors rather than the discussions of specific traumas.
Cognitive therapy	CT	CT mainly uses cognitive restructuring training, which aims at examining youths' automatic thoughts and core schemas and evaluating the accuracy and affective consequences of their views. They aim to teach youths to engage in "rational" thinking about themselves, the traumatic incident, and the world.
Behavioral therapy	BT	BT uses some form of behavioral training, especially for exposure -based therapy and narrative therapy, to help youth reduce trauma-related symptoms. BT is based on principles of habituation.
Eye movement desensitization and reprocessing	EMDR	EMDR aims to help a person reprocess their memories of a traumatic event. The therapy involves bringing distressing trauma-related images, beliefs, and bodily sensations to mind.
Psychodynamic therapy	DYN	Psychodynamic psychotherapy focuses on integrating the traumatic experience into the life experience of the individual as a whole. Childhood issues are often felt to be important.
Play therapy	PT	PT used techniques to engage participants in recreational activities to help them cope with their problems and fears.
Stress management	SM	SM mainly includes some form of relaxation or biofeedback
Supportive therapy	ST	ST is an unstructured therapy without specific psychological techniques that it helped people to ventilate their experiences and emotions and offering empathy. e.g. supportive counseling, attention control, minimal contact, active listening, common factor control, nonspecific control
<i>Control conditions:</i>		
Treatment-as-usual	TAU	TAU is often described as "usual care" or "usual community treatment" in trials, which may include any components of psychotherapy or pharmacotherapy for PTSD. It is not considered to be structured intervention but may have some treatment effects.
Waitlist	WL	WL is a control condition in which the participants receive no active treatment during the study but are informed that they can receive one after the study period is over.
No-treatment	NT	NT is a control condition in which the participants receive no active treatment during the study and in which they do not expect to receive such after the study is over.

Table 2 Hierarchy of PTSD symptom severity measurement scales

Hierarchy	PTSD symptom severity rating scales	Abbreviation
1	UCLA Posttraumatic Stress Disorder Reaction Index	UCLA PTSD Index
2	Child PTSD Symptoms Scale	CPSS
3	Clinician-Administered PTSD Scale/ Clinician Administered PTSD Scale-Child and Adolescent Version	CAPS/ CAPS-CA
4	Impact of Events Scale/ The Children's Revised Impact of Events Scale	IES/ CRIES
5	Parent report of post-traumatic symptoms/Child report of post-traumatic symptoms	PROPS/CROPS
6	Kiddie-Schedule for Affective Disorders and Schizophrenia	K-SADS
7	Trauma Symptom Checklist for Children	TSCC
8	Posttraumatic Cognitions Inventory/Child post-traumatic cognitions inventory	PTCI/CPTCI
9	Harvard Trauma Questionnaire	HTQ
10	Post traumatic Stress Scale	PSS
11	Child Post-Traumatic Stress-Reaction Index	CPTS-RI
12	The Preschool Age Psychiatric Assessment	PAPA
13	Anxiety Disorders Interview Schedule	ADIS

The full search strategy for PubMed

The following explicit search strategy with filters of clinical study will be applied: Condition = [(post-traumatic* or PTSD or PTSS or posttrauma* or trauma* or peritrauma* or peri-trauma* or psychotraumatology or “stress disorder*” or “stress reactions” or “sexually abus*” or “sexual abus*” or “sexually assault*” or “sexual assault*” or “physical abuse*” or “physically abuse*” or “child abuse” or “children abuse” or “natural disaster” or refugee or war or violence or maltreat* or mistreat or acciden* or tsunami* or hurricane* or earthquake or tornado)] AND Intervention = (“trauma focused” or trauma-specific or cogniti* or behavio* or CBT or “eye movement desensitization and reprocessing” or EMDR or EMD or “stress management” or “stress inoculation training” or mindfulness or “art therapy” or “play therapy” or hypnotherapy or biofeedback or counsel* or supportive or interpersonal or bibliotherapy or narrative or narration or exposure* or psychoeducation or “family treatment” or “family therapy” or meditation or relaxation or “problem solving” or “school-based intervention” or “school-based treatment” or “mind-body skills” or “seeking safety” or “mental health” or “writing for recovery” or “psychosocial intervention” or “child centered” or psychodynamic or psychodrama or desensitization or psychological or psychotherap*) AND Age = (adolesc* or boy* or girl* or child* or infant* or juvenil* or minors or pediatri* or paediatric* or pubescen* or puberty or student* or teen* or young or youth* or school* or high-school or preschool* or pre-school* or class*).

The following Medical Subject Headings (MeSH) will also be searched: “Stress Disorders” AND “Psychotherapy” AND (“child” OR “adolescent”).

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Reported on Page #
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	4
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	17
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	
Support:			
Sources	5a	Indicate sources of financial or other support for the review	17
Sponsor	5b	Provide name for the review funder and/or sponsor	17
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	17
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	6-7
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	7-8
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	8-11
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	12
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be	Supplementary

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

	repeated		material
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	12
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	12-13
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	13
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	13
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	10-11
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	13
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	13-14
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	14
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	14-15
Meta-bias(es)	16	If quantitative synthesis is not appropriate, describe the type of summary planned	15
Confidence in cumulative evidence	17	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	15

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.